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Viral respiratory and gastrointestinal infections are a major health problem, in particular 
among children. A large range of etiologic agents and increasing antiviral and antibiotic 
resistance, challenge the development of efficient therapies. Accumulating evidence suggests 
that specific probiotic bacteria are able to decrease the risk and symptoms of these infections. 
This thesis investigated the effects of specific probiotics, in particular Lactobacillus 
rhamnosus GG, on respiratory and gastrointestinal virus infections in a cell model in vitro, in 
a rat model in vivo, and in children. A particular focus was on questions, whether viability of 
a probiotic is an important factor in probiotic-virus interaction, and whether a combination 
of probiotics is more effective than single strains.  
 
A novel colorimetric neutralization assay was developed for measuring influenza virus 
antibodies in human sera. The method was applied to measure antibody response after the 
administration of a seasonal, inactivated, trivalent influenza vaccine. The results were 
compared with those obtained with a traditional hemagglutinin inhibition test. The results 
obtained with both assays correlated well. Moreover, neutralization test proved to be more 
sensitive and specific than the hemagglutinin inhibition test.  Thus, the method is valid for 
influenza virus research, and it could be applied for studying immune adjuvant effects of 
probiotics on serum influenza antibody titers in the future. 
 
Immunomodulatory effects of probiotics were screened in human macrophage model in 
vitro. After 24 hours of bacterial stimulation, probiotic combination of L. rhamnosus GG and 
L. rhamnosus Lc705 was not able to significantly induce higher macrophage cytokine and 
chemokine production (TNF-α, IL-1β, IL-6, IL-10, and IL-12, MCP-1, IP-10) over individual 
L. rhamnosus strains. However, cytokine responses induced by this combination were 
stronger than responses induced by traditional starter culture bacterium Lactococcus lactis 
ARH74, highlighting that immunomodulatory effects of probiotics are strain specific.  
 
The effects of live and unviable L. rhamnosus GG in rotavirus infection were investigated in a 
neonatal rat model. Consistency of feces, animal weight, colon weight and the rotavirus 
colonization of plasma and intestinal tissues were considered as indexes of infection severity. 
Nonviable L. rhamnosus GG had beneficial effects in rotavirus infection in terms of reducing 
rotavirus induced body weight reduction and colon weight increase. However, live L. 
ABSTRACT 
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rhamnosus GG was more effective in reducing significantly viral load in the gastrointestinal 
tract.  
 
The effects of L. rhamnosus GG alone or probiotic combination containing L. rhamnosus GG 
on the occurrence of viral respiratory infections was assessed in a six month intervention trial 
in children or in otitis-prone children.  Children receiving only L. rhamnosus GG had fewer 
days with respiratory tract symptoms during the intervention period. However, L. 
rhamnosus GG did not reduce viral occurrence in the nasopharynx, suggesting that L. 
rhamnosus GG is able to reduce respiratory virus symptoms through enhancing immune 
response. 
 
 In otitis-prone children, L. rhamnosus GG in a combination with L. rhamnosus Lc705, 
Bifidobacterium breve 99, and Propionibacterium freudenreichii ssp. shermanii JS 
significantly reduced human bocavirus load in the nasopharynx three to six months after 
intervention.  
 
In conclusion, probiotics and their combinations differ in their ability to elicit 
immunomodulatory effects in vitro. Viability of a probiotic is an important factor in virus 
infection. The probiotic L. rhamnosus GG reduced days with respiratory tract symptoms. In 
children, L. rhamnosus GG alone was not effective in reducing viral occurrence in the 
nasopharynx. However in otitis-prone children, L. rhamnosus GG in a combination reduced 
the numbers of human bocavirus. 
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Viral respiratory and gastrointestinal infections in children pose a considerable health 
and economic burden in terms of hospitalizations, medical costs, doctor’s consultations, and 
absenteeism from work and school. Currently, the only effective antivirals and vaccines for 
the prevention and treatment of respiratory virus infections are available against influenza 
viruses. Large varieties of other etiologic agents and increasing antibiotic and antiviral 
resistance challenge the development of efficient therapies. Consequently, it is of importance 
to find alternative and safe ways to reduce the risk of these infections.  Moreover, with 
constantly evolving viruses and the introduction of novel viruses, there is a clear need for new 
sensitive and specific methods for identifying virus infections in order to provide more 
accurate virological diagnoses and properly direct antiviral therapy.  
 
Probiotics are defined as live microorganisms that confer a health benefit on the host 
(FAO/WHO, 2002). The most common types of microbes used as probiotics are lactobacilli 
and bifidobacteria, which are generally consumed as part of fermented foods, such as in 
yogurts or as dietary supplements. Considering beneficial effects of probiotics in virus 
infections, specific probiotics have been suggested to be effective in alleviating the duration 
and severity of acute rotavirus gastroenteritis (Guarino et al., 2009). In addition, probiotics 
are able to reduce the risk of respiratory tract infections in children (Hatakka et al., 2001, 
Cobo Sanz et al., 2006, Hatakka, 2007., Hojsak et al., 2010a, Hojsak et al., 2010b, Taipale et 
al., 2011), which in most cases are of viral origin. However, the mechanisms behind these 
beneficial effects are largely unknown. Probiotics are likely to have an impact through gut 
mucosa by balancing the local microbiota (Madden et al., 2005), by inhibiting the growth of 
pathogenic microorganisms (Servin, 2004), and by enhancing local and systemic immune 
responses (Bodera and Chcialowski, 2009). They may also influence the composition and 
activity of microbiota in the intestinal contents.  However, there are virtually no comparative 
clinical studies of probiotics effectiveness against respiratory tract infections. 
 
In recent years products containing multispecies probiotics have been launched into markets. 
However, evaluation data whether they elicit synergistic beneficial effects or antagonistic 
effects over single strains is scarce. In addition, increasing evidence shows that 
killed/nonviable bacteria, products derived from bacteria, or end products of bacterial 
growth could provide some health benefits (Kataria et al., 2009, Lahtinen and Endo, 2011). 
These nonviable bacteria would serve as a great potential for food industry in terms of 
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providing new product applications, increasing product shelf life, and reducing storage costs. 
However, more data concerning health effects of nonviable probiotics are necessary. 
 
The aim of this thesis was to characterize the effects of probiotics especially L. rhamnosus GG 
on respiratory and gastrointestinal virus infections in experimental models and in children. A 
particular focus was on questions, whether viability of a probiotic is an important factor in 
probiotic-virus interaction, and whether a specific combination of probiotics is more effective 
than single strains. 
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1 COMMON VIRAL INFECTIOUS DISEASES IN CHILDREN 
 
1.1 RESPIRATORY VIRUS INFECTIONS 
 
Viral respiratory tract infections (RTI) are a major cause of morbidity and mortality 
worldwide particularly in children (Denny et al., 1986, Heikkinen and Järvinen, 2003). On 
average children suffer annually from 5-10 RTIs during the first years of life (Lumio, 2010). 
According to global annual estimates two million children die from acute RTIs, which 
account for 10-20 % of all childhood deaths (Williams et al., 2002). The social and economic 
impact of respiratory viral disease is substantial due to hospitalizations, medical costs, 
missed work, and school and day care absences. For instance, viral RTIs lead to over 400,000 
annual hospitalizations in children under 18 years of age in the United States alone (Nichols 
et al., 2008). Children attending day care are especially at risk for acquiring RTIs (Denny et 
al., 1986, Louhiala et al., 1995) as close physical contact among children in day care favors the 
transmission of infectious diseases. 
 
RTIs are typically classified into upper and lower RTIs. Upper RTIs affect the nose, sinuses, 
throat, and the ear, whereas lower RTIs affect airways and lungs. Common infections of 
upper RTIs are acute upper RTI (common cold), otitis media, otalgia, tonsillitis, sinusitis, 
and laryngitis involving symptoms such as cough, sore throat, runny nose, nasal congestion, 
headache, low grade fever, and sneezing (Eccles, 2007). The majority of lower RTIs are 
bronchitis and pneumonia, which are clinically characterized by a variety of symptoms like 
cough, fever, wheezing, chills, and chest pain (Marrie, 2000).  The most common viral RTIs 
in children are the common cold and acute otitis media (AOM). 
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1.1.1 Etiology and clinical manifestations 
 
In humans over 200 types of viruses may cause RTIs. In upper RTIs, human rhinovirus 
(HRV), respiratory syncytial virus (RSV), and parainfluenza virus (PIV) are considered the 
major pathogens, followed by human enterovirus (HEV), influenza virus, and adenovirus 
(ADV). Influenza virus, PIV, and RSV cause more symptoms in the lower respiratory tract 
(Table 1) (Heikkinen and Chonmaitree, 2003, Nokso-Koivisto et al., 2006, Ruuskanen et al., 
2011). Although viruses tend to have some variation in their typical clinical manifestation, it 
is not possible to identify the causative virus on the basis of symptoms. 
 
Most respiratory viruses follow seasonal occurrence: In the Northern hemisphere, the 
frequency of  viral RTIs increases rapidly in the autumn, reaching peak incidence during 
winter, and decreases again in the spring (Butz et al., 1990, Rautakorpi et al., 2006).  
 
Table 1. The most common viral causative agents of RTIs in children.  
Virus 
Upper RTIs            Lower RTIs 
Common 
cold 
Otitis 
media Tonsillitis Laryngitis   Bronchitis Bronchiolitis Pneumonia 
Rhinovirus + + 
      Enterovirus + 
 
+ 
     Influenza 
virus + + + + 
 
+ + + 
Respiratory 
syncytial virus 
 
+ + + 
 
+ + + 
Parainfluenza 
virus + 
  
+ 
 
+ + + 
Metapneumo- 
virus 
      
+ 
 Adenovirus 
  
+ 
    
+ 
Bocavirus 
 
+ 
     
+ 
Coronavirus +               
 
 
Rhino- and enteroviruses 
 
 Human rhinoviruses (HRV) and enteroviruses (HEV) are non-enveloped, positive-
stranded RNA viruses HRVs are also the largest group of respiratory viruses, including over 
100 serotypes. In children the predominant illness caused by HRV is the common cold. 
Frequently HRV infection results in a mild illness characterized by a runny and stuffy nose, a 
sore throat, coughing, and hoarseness (Lina et al., 1996, Arruda et al., 1997, Monto et al., 
REVIEW OF THE LITERATURE 
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2001, Gwaltney Jr., 2002).  More severe symptoms resembling influenza may also occur 
(Boivin et al., 2002). HRV is very common in children with AOM as well (Pitkäranta et al., 
1998, Nokso-Koivisto et al., 2004), and is associated with acute lower RTIs infections such as 
wheezing, bronchiolitis, and pneumonia (Chidekel et al., 1997, Kim and Hodinka, 1998, 
Hayden, 2004).  
 
HEVs are commonly associated with clinical manifestations ranging from mild respiratory 
symptoms to serious conditions, including aseptic meningitis, encephalitis, neonatal sepsis, 
and acute flaccid paralysis. In addition, HEVs are a common cause of upper RTI and AOM 
(Ruohola et al., 2000, Nokso-Koivisto et al., 2004).  
 
Influenza viruses 
 
Influenza viruses are RNA viruses with segmented genome.  Influenza viruses are divided 
into three distinct types namely A, B, and C based on their structural and antigenic 
properties.  Influenza A viruses are divided further into subtypes based on the variation on 
viral glycoproteins hemagglutinin and neuraminidase.  Most human RTIs are caused by types 
A and B, which are responsible for annual influenza epidemics due to antigenic drift. 
Influenza A and B viruses cause infections ranging from asymptomatic infections and 
common colds to serious illnesses with systemic complications such as pneumonia (Mäkelä 
et al., 1998, Zambon, 1999). Influenza virus infection also disposes children to secondary 
bacterial infections such as sinusitis, otitis media, and pneumonia (Heikkinen and 
Chonmaitree, 2003). Typically, the attack rates during the annual outbreaks of influenza are 
highest in children, affecting on average of 20–30% of the pediatric population (Fraaij and 
Heikkinen, 2011).  
 
Respiratory syncytial virus  
 
Both RSV and PIV belong to the family of Paramyxoviridae, which are enveloped RNA 
viruses with single-stranded (ss) genome.  There are two major groups of RSV (A and B), and 
both strains may circulate and cause concurrent infections (Peret et al., 1998). RSV is the 
leading cause of bronchiolitis and acute wheezing in young children accounting also for 
approximately 50% of all pneumonia cases (Langley and Anderson, 2011). In immune-
compromised patients, RSV infection may cause respiratory failure leading to mortality rates 
exceeding 70% (Glezen et al., 1986, Hertz et al., 1989). In the United States, 60% of infants 
REVIEW OF THE LITERATURE 
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are infected during their first RSV season, and nearly all children have been infected with the 
virus by 2–3 years of age (Glezen et al., 1986). 
 
Parainfluenza virus  
 
        Four types of PIV are infecting humans. PIV 1-3 occur worldwide and among persons 
from all age groups, whereas PIV 4A and 4B are much less frequent. PIV can cause a broad 
spectrum of respiratory diseases, ranging from mild upper RTIs to pneumonia, but are most 
often associated with laryngitis (Knott et al. 1994). PIV infections are most severe in infants 
and become less severe with age. PIV 1-3 are the main causes of croup in infants and young 
children under five years of age, and these viruses also cause viral pneumonia and 
bronchiolitis (Knott et al., 1994, Marx et al., 1997, Laurichesse et al., 1999, Rihkanen et al., 
2008).  
 
Metapneumoviruses  
 
              Human metapneunovirus (hMPV) is an enveloped ssRNA virus, which was originally 
isolated from respiratory tract samples of children with respiratory disease in 2001 (Van den 
Hoogen et al., 2001). hMPV causes upper and lower RTIs in all ages, but mostly in children 
under five years of age (Jartti et al., 2012). Currently, hMPV is recognized second to RSV as a 
cause of bronchiolitis in early childhood (Mullins et al., 2004, Williams et al., 2004, Chano et 
al., 2005, Feuillet et al., 2012). 
 
Adenoviruses 
 
Human ADVs are non-enveloped DNA viruses with double-stranded (ds) genome. ADVs 
are divided into seven species (A-G) containing 56 serotypes (Robinson et al., 2011). Certain 
clinical presentations of ADV RTIs are linked to particular serotype.  For instance respiratory 
illnesses are attributed mainly to species ADV B and C, whereas ADV-F types 40, 41, and 
ADV-G type 52 are responsible for gastroenteritis. In children, the usual clinical presentation 
of RTI caused by ADV includes upper respiratory symptoms (rhinorrhea, cough) and lower 
respiratory tract symptoms (Rowe et al., 1953). In addition, ADV infection is frequently 
associated with pharyngoconjunctival fever and epidemic conjunctivitis (Edwards et al., 
1985). 
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Bocaviruses 
 
Human bocavirus (HBoV) is a non-enveloped, ssDNA virus. HBoV1 was discovered in 
2005 using molecular screening from nasopharyngeal aspirates of children with RTIs 
(Allander et al. 2005).  Later on, HBoV 2-4 have been identified in children’s fecal samples 
(Arthur et al. 2009, Kapoor et al. 2009, Kapoor et al. 2010). HBoV1 has been detected 
globally mostly in respiratory samples with 1.5–19% prevalence but also in stool, serum, 
tonsillar, saliva, and urine samples (Jartti et al., 2012). HBoV1 is associated with upper and 
lower RTIs, and most notably with pneumonia, otitis media, and acute wheezing in children 
(Allander et al., 2007, Kantola et al., 2008, Söderlund-Venermo et al., 2009, Kantola et al., 
2010, Meriluoto et al., 2012). HBoV2-4 have been found mainly in fecal samples of children, 
and HBoV2  seems to be the most prevalent of causing gastroenteritis (Jartti et al., 2012).  
 
Coronaviruses 
 
Human coronaviruses are enveloped viruses with a large positive-stranded RNA genome. 
Altogether five types of coronaviruses have been identified causing respiratory illnesses in 
humans. The first two, 229E and OC43 were identified in the 1960s (Tyrrell and Bynoe, 1965, 
McIntosh et al., 1967). In 2003-2005, three new coronaviruses SARS, HKU1 and NL-63 were 
identified from patients with respiratory symptoms (Drosten et al., 2003, Van der Hoek et al., 
2004, Woo et al., 2005). Coronaviruses 229E, OC43, HKU1 and NL-63 have been in 
continuous circulation since their first isolation, and cause annually a large number of upper 
and lower RTIs in children (Brodzinski and Ruddy, 2009, Principi et al., 2010). 
1.1.2 Pathogenesis 
 
The understanding of the pathogenesis of respiratory viruses has important implications 
for the development of therapies against common colds. The pathogenetic mechanisms of 
respiratory viruses differ between the viruses (Figure 1).  Transmission of the virus may 
occur by direct inoculation of contagious secretions from the hands, or by large or small 
particle aerosols into the eyes and nose, and requires close or direct contact with large 
droplets or fomites (Boone and Gerba, 2007). Respiratory viruses target mainly the epithelial 
and bronchial cells of the upper and lower respiratory tract.  The incubation period takes 
approximately 2-15 days depending on the virus. For instance, in HRV infection the first 
symptoms occur soon after virus entry into the nasopharynx and peak on 2-3 days of 
infection (Brownlee and Turner, 2008).  HRV infection typically starts with a sore throat, 
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soon followed by watery nasal discharge, and later by nasal congestion and cough, which may 
persist for over three weeks (Eccles, 2005). RSV and PIV replicate in the nasopharyngeal 
epithelium, and spread to the lower respiratory tract 1-3 days later possibly via direct spread 
along the respiratory epithelium, or through the aspiration of nasopharyngeal secretions, or 
through macrophages (Domachowske and Rosenberg, 1999).  Influenza viruses 
predominantly attach to the tracheal and bronchial epithelial cells causing typically a high 
fever (40oC), headache, nausea, and chills within 1-4 days (Peltola et al., 2003). In addition, 
efficient virus replication, maintenance of viral protein synthesis, shut-down of host protein 
synthesis, and production of viral particles lead usually to cytolytic death of cells at 20–40 
hours of infection (Julkunen et al., 2001). In the host, viral replication and cellular damage 
evokes inflammatory and immune responses, leading to vasodilatation, increased vascular 
permeability and cellular infiltration through the release of inflammatory mediators. 
Increased concentrations of proinflammatory and chemotactic cytokines in nasal lavage 
result in a cascade of inflammatory reactions necessary for viral eradication (Van Kempen et 
al., 1999, Julkunen et al., 2001). The characteristic inflammation of RSV bronchiolitis is 
necrosis and sloughing of the epithelium of the small airways with edema and increased 
secretion of mucus, which obstructs flow in the small airways. The resulting clinical findings 
are the hallmarks of bronchiolitis: hyperinflation, atelectasis, and wheezing (Hall, 2001). 
Viral infections also dispose to secondary bacterial infections such as Streptococcus 
pneumoniae, leading to bacterial complications in the upper respiratory tract (such as AOM 
and sinusitis) (Osur, 2002, Heikkinen and Chonmaitree, 2003), or in the lower respiratory 
tract (such as bronchitis and pneumonia) (Peltola et al., 2004, Peltola et al., 2006). Viral 
infections upregulate receptors utilized by bacteria, which facilitate bacterial adherence and 
colonization (Hament et al., 1999, Peltola and McCullers, 2004). Moreover, virus induced 
physical damage in the respiratory epithelium may impair the local defense mechanisms, 
which leads to increased translocation of bacteria through the epithelial barrier of the 
respiratory cells. 
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Figure 1. Schematic illustration of pathogenesis of respiratory viruses in the host. Adapted 
from Fields’ virology 2007 (Fields et al., 2007). 
1.2 GASTROINTESTINAL VIRUS INFECTIONS 
1.2.1 Etiology and clinical manifestations 
 
Acute viral gastroenteritis is a worldwide cause of infant morbidity and mortality in 
developed and developing countries. Viruses that cause gastroenteritis in humans include 
rotaviruses (RV), caliciviruses (noroviruses), sapoviruses, astroviruses, enteric ADVs 
(serotypes 40 and 41), and Aichi virus (Ciarlet and Estes, 2001).  Among these, RV is the 
etiologic agent of greatest medical and epidemiologic importance in young children and 
infants accounting annually for nearly 450 000 child deaths worldwide (Tate et al., 2012). In 
Finland after the introduction of RV vaccine in 2009, norovirus infections have become as 
common as RVs as the causative agents of acute gastroenteritis in young children (Puustinen 
et al., 2011, Räsänen et al., 2011a).   
 
RVs are dsRNA viruses belonging to the Reoviridae family. RV form seven antigenically 
different main groups named A-G. Group A-C infects humans, of which group A is the most 
common.  Other groups (E-G) have been identified only in animals. There are also different 
serotypes within RV A group, and the classification is based on two structural proteins on the 
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surface of the virion. The glycoprotein VP7 defines G-types and the protease-sensitive protein 
VP4 defines P-types. In temperate latitudes RV infection occurs most frequently in winter.  
The disease is characterized by vomiting and watery diarrhea for 3-8 days. Fever and 
abdominal pain occur frequently. Vomiting generally lasts for 24 hours from the onset, 
whereas watery diarrhea persists longer, and is the predominant sign of RV infection. 
Immunity after infection is incomplete, but repeat infections tend to be less severe than the 
original infection (Rodriguez et al., 1977, Velazquez et al., 1996).  
1.2.2 Pathogenesis of rotavirus infection 
 
Life cycle of rotavirus 
 
As a distinction for respiratory virus life cycle, RVs replicate mainly in the gut, and infect 
enterocytes of the villi of the small intestine leading to structural and functional changes of 
the epithelium. RV virion consists of triple protein coats, which provide resistance to the 
acidic pH of the stomach and the digestive enzymes in the gut.  Several cell-surface molecules 
have been implicated in the early interactions of RV with its host cell, including sialic acid, 
various integrins, heat shock protein 70, and gangliosides. RV enters into the cells by 
receptor mediated endocytosis and forms an endosome vesicle. Viral proteins in the third 
layer (VP7 and VP4) disrupt the membrane of the endosome, creating a difference in the 
calcium (Ca) concentration, and leading to the distruption of outer layer proteins. This event 
triggers the uncoating of the virus to a double-layered particle, and the activation of the viral 
transcriptase. A special viroplasm is formed around the cell nucleus, where viral RNA is 
replicated, translated proteins accumulate, and the double-layered RV particles are 
assembled. These particles migrate to the endoplasmic reticulum where they obtain third 
outer layer (formed by VP7 and VP4). Finally, the progeny of viruses are released from the 
cell by lysis (Greenberg and Estes, 2009). 
 
Pathogenesis 
 
RV is transmitted by the fecal-oral route via contact with contaminated hands, surfaces 
and objects (Butz 1993) with small infectious doses (≥one plaque forming unit, pfu) (Graham 
et al., 1987). During the incubation period of approximately two days, RV enters the epithelial 
cells and replicates causing diarrhea. RV continues to destroy the epithelium leading to 
extensive damage, and shedding of extensive masses of virus in the stools (Glass et al., 2006). 
The diarrhea  is caused by multiple activities of the virus (Greenberg and Estes, 2009,  Liu et 
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al., 2009):  a) RV replication inside the enterocytes causes altered metabolism of enterocyte 
membrane proteins inducing malabsorptive or osmotic diarrhea, b) RV increases the 
concentration of intracellular calcium (Ca) distrupting the cytoskeleton and the tight 
junctions, and raising paracellular permeability, c) RV produces NSP4, a toxin that induces a 
Ca- dependent signal transduction pathway leading to increasing Ca2+ concentration. In 
addition, NSP4 produced by the infection disrupts tight junctions  allowing paracellular flow 
of water and electrolytes, d) RV can stimulate the enteric nervous system, inducing secretory 
diarrhea and increasing intestinal motility, e) enterocyte cell death also contributes to 
malabsortive or osmotic diarrhea. Primary RV infection in the host leads to a serotype-
specific humoral immune response in the intestine and serum providing initial monotypic 
protection. During the first two years of life, children are repeatedly infected with various 
types of RV, resulting in a more complex immune response, which seems to provide partial 
heterotypic protection (Velazquez et al., 1996). RV-specific secretory IgA antibodies in the 
serum seem to provide the best protection (Franco et al., 2006). 
1.3 LABORATORY DIAGNOSIS OF VIRUS INFECTIONS 
 
The laboratory diagnosis of virus infections is based on the identification of viruses or 
virus particles from clinical samples, or demonstration of a rise in virus specific antibody 
titers between acute and convalescent serum samples. Diagnosis of RV infection normally 
follows diagnosis of acute gastroenteritis as the cause of severe diarrhea. Most children 
admitted to hospital with gastroenteritis are tested for group A RV (Patel et al., 2007).  
Reliable diagnosis of respiratory virus infections, however, is challenging because of the high 
number of potential viral agents causing similar signs of symptoms of respiratory illness. It is 
potentially of importance to rapidly diagnose respiratory viruses in order to properly direct 
antiviral therapy, as some antivirals (e.g. against influenza) are only effective if administered 
in the early stages of infection. Rapid viral diagnosis significantly also decreases length of 
hospital stays and unnecessary laboratory testing (Henrickson, 2005). In addition, 
understanding the actual cause of disease also decreases unnecessary use of antibiotics in 
viral RTIs (Gonzales et al., 2001). Prior the development of molecular diagnostics such as 
polymerase chain reaction (PCR), viruses were primarily identified by virus isolation in tissue 
culture, or antibody and antigen detection using immunological methods, including enzyme 
linked immunoabsorbent assay (ELISA) or direct and indirect immunofluorescence (IF) 
assays. The comparison of novel and traditional virological methods are summarized in 
Table 2. 
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1.3.1 Traditional detection and isolation methods 
 
The principal classical techniques for detecting and isolating respiratory and 
gastrointestinal viruses are indirect cell culture methods and direct electron microscopy (EM) 
(Mahony, 2008, Beck and Henrickson, 2010).  Most respiratory viruses can be detected by 
virus specific cell lines allowing both quantification and isolation of the virus. The presence of 
a replicating virus in the cell culture can be detected with cytopathic effect or 
haemadsorption. Virus culture is beneficial for culturing a wide variety of viruses (including 
novel and unknown viruses), and obtaining infectious virus particles for biological 
characterization with relatively low cost. In addition, biological responses such as resistance 
to antivirals are obtained only with the cell cultures or inhibition assays. However, 
disadvantages with the virus culture are taking time to results, expertise required for result 
interpretation, careful sample preservation, and low sensitivity. For the improvement of 
these characteristics, IF or molecular tests have been utilized for confirmation and 
identification. In addition, modified culture methods (e.g. shell vial culture) which allow 
faster detection, are commonly used for isolation of respiratory viruses. 
 
In EM, virus particles are detected and identified on the basis of virus morphology. EM is 
mainly used for the diagnosis of viral gastroenteritis such as RV. The main problem with EM 
is the expense involved in purchasing and maintaining the facility. In addition, the sensitivity 
of EM is often poor, as at least 105 to 106 virus particles per ml in the sample is required for 
visualization. As reliable antigen detection and molecular methods for identification of all 
species and serotypes of gastroinstestinal viruses from environmental samples, serum, and 
cerebrospinal fluids have been developed, EM is becoming less and less widely used 
(Wilhelmi et al., 2003). 
1.3.2 Immunological methods 
 
The majority of immunological methods are based on viral antigen detection using 
monoclonal antibodies, which rely on IF or ELISA technologies. IF is widely used for 
respiratory virus detection from nasopharyngeal specimens, and ELISA for detection of RV 
antigen in feces. IF utilizes specific fluorescent labeled monoclonal antibodies which bind to 
viral antigens. ELISA techniques are based on enzymatic reaction, where coated primary 
antibody binds to viral antigen from the sample, and the positive reaction is identified using 
enzyme conjugated secondary antibody. The main advantage of IF and ELISA is that they are 
rapid to perform with the result being available within a few hours. However, IF is difficult to 
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read and interpret with sometimes poor specificity and sensitivity. A number of commercial 
products are available for the diagnosis of RV and respiratory viruses, including screening 
kits for the detection of up to seven respiratory viruses (Beards et al., 1984, Landry and 
Ferguson, 2000). 
1.3.3 Serology 
 
Serology allows the identification of virus specific antibodies from serum samples, such as 
recognition of IgM in primary/acute infection, and the detection of rising titers of antibody 
between acute and convalescent stages of infection (IgG immunity).  Hemagglutination 
inhibition test (HI), ELISA, radioimmunoassay, complement fixation test, and virus 
neutralization tests (NT) are widely used. HI is based on the ability of a certain virus (e.g. 
influenza) to agglutinate the erythrocytes of mammalian or avian species causing 
hemagglutination of the cells. Hemagglutination is prevented if serum contains antibodies 
against the viral protein responsible for hemagglutination. By serially diluting the sample, the 
amount of antigen can be quantified in an unknown sample by its titer. In addition HI allows 
subtyping of influenza A virus. However, the specificity of the HI test varies with different 
viruses. In NT method, neutralization of a virus is defined as the loss of infectivity through 
binding reaction of a specific antibody to a virus. When virus and serum sample are mixed 
under appropriate condition and inoculated into cell culture, the presence of unneutralized 
virus may be detected by cytopathic effect, enzyme immunoassay, or plaque formation.  The 
sensitivity and specificity of the assays depend greatly on the antigen used. For respiratory 
and gastrointestinal virus infections, which produce clinical disease prior appearance of 
antibodies, serological diagnosis is retrospective. For the diagnosis of influenza infections, 
however, serology may be important and cost-effective during an influenza epidemic. 
1.3.4 Molecular diagnostics 
 
Diagnosis of viral infections has been revolutionized by the development of molecular 
techniques, principally with the applications of PCR. PCR techniques allow rapid 
identification of viral genomes from clinical specimens within 2-24 hours from sample 
collection.  Another significant advantage is sensitivity, as PCR methods can detect several 
orders of magnitude less of a target virus than tissue culture. In general, viral diagnosis with 
PCR involves three main steps: First, viral nucleic acid (DNA or RNA) is extracted from the 
clinical sample. Second, fragments of the genome are amplified using virus-specific primers. 
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Prior amplification, detection of RNA viruses generally requires also an additional step where 
RNA is reverse-transcribed (RT) into cDNA. Third, the amplified viral genome is visualized 
with either traditional stained agarose gel or in a real-time PCR assay.  Real-time PCR assays 
have additional advances over conventional PCR, as the inclusion of an additional fluorescent 
probe detection system allows increased sensitivity, the ability to confirm the amplification 
product, and to quantitate the target concentration.  More recently, multiplex detection 
strategies have been developed, which allow sensitive detection of over ten viral pathogens 
simultaneously (Templeton et al., 2004, Li et al., 2007, Wang et al., 2009).  Although PCR 
assays are sensitive, PCR is highly prone to contamination, which may result in false positive 
results. This may lead to inaccurate diagnosis, and to more serious complications. Instead of 
infective virus, PCR assays detect genomic material from the specimen. As some respiratory 
viruses are detectable in asymptomatic patients, the results may also indicate a past infection 
(Jartti et al., 2004, Winther et al., 2006, Wright et al., 2007).  
 
In summary, many virological methods are available for virus diagnostics depending on 
the study material used. Molecular diagnostics has significantly improved the laboratory’s 
ability to diagnose viral RTIs. In order to provide more accurate virological diagnoses, 
existing methods with increased sensitivity need to be constantly improved. In addition, 
new diagnostic tests will be required to determine the impact of novel virologcial agents, 
and assist clinicians in the management of patients. 
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Table 2.  Traditional and molecular virological diagnostic methods. 
Diagnostic 
methods Technique Discovery Target Advantages Disadvantages 
Virus 
isolation 
Cell culture 
 
1940s
a
 
 
Cytopathic 
 effect, 
Hemabsorption 
Detection of wide 
variety/novel viruses 
Biological 
characterization 
Low cost 
Time consuming 
Requires 
expertise 
Low sensitivity  
     
Electron  
microscope 
 
1930s
b
 Virus 
morphology 
Specific Mainly for 
gastrointestinal 
viruses 
Low sensitivity 
High maintenance 
costs 
 
Immunological  
methods 
 
 
IF 
 
 
 
 
ELISA 
 
 
1950s
c 
 
 
 
 
1960s
d
 
Virus antigen 
detection 
 
 
 
Virus antigen 
detection                                         
 
 
Rapid 
Screening of  
multiple viruses  
 
 
Rapid 
Sensitive
Difficult result-
interpretation 
Poor sensitivity 
and specificity 
 
Specificity may 
vary 
 
Serology HI 
NT 
ELISA 
 
1950s
e 
1970s
f
 
Virus specific 
antibodies 
Identification of 
primary infection 
Viral subtyping 
Sensitive and specific 
Specificity 
may vary  
Requires 
expertise 
Molecular  
diagnostics 
PCR-
techniques 
1980s
g 
 
Virus genome Rapid 
Sensitive and specific 
Screening of multiple 
viruses 
High 
contamination 
risk 
a 
Enders et al., 1949 
b 
Hazelton and Gelderblom, 2003 
c 
Marshall Jr., 1951
 
d 
Yalow and Berson, 1960
 
e 
Donald and Isaacs, 1954 
f 
Schmidt et al., 1976 
e 
Shampo and Kyle, 2002, Zaia and Rossi, 1989 
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1.4 TREATMENT AND PREVENTION 
 
Children are at increased risk for acquiring respiratory and gastrointestinal infection in 
day care centers and during a hospital stay (Denny et al., 1986, Raymond et al., 2000, Lu et 
al., 2004).  Viral infections are preventable by interrupting viral transmission by maintaining 
good hygiene, and cleaning all surfaces with suitable disinfectants. For instance, respiratory 
viruses can survive few hours in contaminated surfaces (Vasickova et al., 2010), and RV for 
several days depending on the environment (Ansari et al., 1991). Environmental spread of 
viruses can be minimized with the use of certain disinfectants (Anderson and Weber, 2004, 
Kramer et al., 2006). Clinical trials also demonstrate that improved hand hygiene, alcohol-
based sanitizers, and disinfectants are effective in reducing viral respiratory and 
gastrointestinal illnesses in children and adults (Uhari and Möttönen, 1999, Mott et al., 2007, 
Gray et al., 2008, Savolainen-Kopra et al., 2012) There are also many options for the 
treatment of respiratory and gastrointestinal virus infections, which are described in more 
detail below. 
1.4.1 Vaccines 
 
         Immunization against respiratory and gastrointestinal virus infections is the most 
efficient way to reduce severe disease incidence. For respiratory viruses, commercially 
available vaccines globally are against influenza. In Finland, the influenza vaccine is also 
included (since 2007) in the routine vaccination programme for all children aged 6-35 
months, which effectively prevents symptomatic influenza infections (Heinonen et al., 2011).  
Influenza vaccination reduces otitis media in the pediatric population as well (Heikkinen et 
al., 1991, Ozgur et al., 2006). In addition, pneumococcal vaccine in Finland has also 
contributed to the reduction of AOM cases in children (Eskola et al., 2001, Kilpi et al., 2003). 
Live vaccines against ADV types 4 and 7 have been approved in the United States for ADV-
associated acute RTI, but only for military population 17-50 years of age. Vaccine 
development against the most common RTI viruses RSV, HRV, and PIV has been ongoing 
without any real success (Sato and Wright, 2008, Hurwitz, 2011, Papi and Contoli, 2011).   
 
Since 1984, RV vaccine has significantly reduced the number of severe acute RV 
gastroenteritis in children (Vesikari et al., 1984, De Vos et al., 2004, Vesikari et al., 2010).  
Currently,  two live RV vaccines containing an attenuated human monostrain (Rotarix®) or a 
combination of five bovine human reassortant strains (RotaTeq®) are approved in most 
countries, and introduced in national immunization programmes of several American, 
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European, Eastern Mediterranean countries, and in Finland (WHO, 2009). In addition, 
based on data from clinical trials evaluating vaccine efficacy in high child mortality countries, 
WHO recommends inclusion of RV vaccination of infants into all national immunization 
programmes.    
1.4.2 Antiviral drugs 
 
All events in the respiratory virus life cycle can be interfered with antiviral agents (Table 
3). Few studies show promising results in blocking viral attachment. For instance in RSV 
infection, binding of monoclonal antibody (palivizumab) to RSV fusion protein inhibits 
fusion of the viral particle with the cell membrane (Scott and Lamb, 1999). Palivizumab is 
currently approved antiviral for the prevention of RSV-associated hospitalization for high-
risk infants. Moreover, a novel peptide molecule with antiviral activity inhibits the binding of 
influenza virus hemagglutinin to its cellular receptor in vitro (Jones et al., 2006). In addition, 
soluble intercellular adhesion molecule-1 (ICAM-1) (tremacamra) molecule inhibits HRV for 
binding to the membrane-bound ICAM-1 on host cells by binding to HRV particles (Turner et 
al., 1999). Pleconaril has been shown to block ICAM-1 receptor, and inhibit HRV attachment 
and HEV uncoating preventing viral replication (McKinlay et al., 1992). However, due to the 
modest efficacy, and drug interactions of these soluble ICAM-molecules, they have not been 
approved for the treatment of common colds (Nichols et al., 2008). Another drug, a capsid 
binding compound BTA-798, was successful in reducing the incidence and severity of HRV 
infection (Thibaut et al., 2012). Adamantanes (amantadine and rimantadine) prevent 
influenza A virus uncoating by inhibiting the M2 membrane protein ion channel activity, and 
block viral replication at an early stage of infection. However, due to the development of high 
levels of resistance to adamantanes among circulating influenza A viruses, they are no longer 
recommended for the prevention of influenza virus infections (Fiore et al., 2011). Viral 
replication and translation can also be inhibited with specific antivirals. For instance, 
cidofovir inhibits ADV DNA synthesis, and shows good clinical efficacy in the eradication of 
ADV and alleviation of symptoms (Waye and Sing, 2010). However, the toxicity profile of the 
substance has limited its clinical use. Some options for blocking or degrading viral mRNA 
molecules are also available, such as small interfering RNAs (siRNA) against RSV, PIV, and 
influenza viruses (Ge et al., 2003, Bitko et al., 2005). Recently, a randomized clinical trial in 
humans with intranasal siRNA targeting RSV nucleoprotein gene showed protective activity 
(DeVincenzo et al., 2010). Moreover, ribavirin blocks the attachment of viral mRNA of RSV, 
PIV, and ADV to ribosomes (Snell, 2001, Gavin and Katz, 2002). Currently, ribavirin as an 
aerosol is approved for the treatment of RSV bronchiolitis in children in the United States.  
REVIEW OF THE LITERATURE 
27 
 
For many respiratory viruses processing of translated polyproteins into smaller biologically 
active proteins with proteases plays a pivotal role in viral gene expression and replication. 
Several different inhibitors of such proteases (e.g rupintrivir) have been described for 
coronaviruses, HRV, and HEV (Rohde, 2007). For the inhibition of viral release from the 
host cells, there are available specific neuraminidase inhibitors against influenza virus 
infection. Zanamivir and oseltamivir are approved drugs against influenza A and B virus 
infections. Both drugs reduce significantly the duration and severity of symptoms with 
infrequent adverse effects (Rohde, 2007). 
 
Table 3.  Options for antiviral drug tragets in the treatment of respiratory virus infections. 
Virus 
Antiviral targets 
Attachment 
Entry/ 
Uncoating 
Replication/ 
Translation 
Posttranslational  
processing 
Relase of 
viral particles 
Rhinovirus 
ICAM-1 receptor 
blocking 
(pleconaril) 
- - 
Protease inhibitor 
(rupintrivir) 
- 
Enterovirus - 
Capsid 
uncoating 
inhibitor 
(pleconaril) 
- - 
Influenza 
virus 
Hemagglutinin 
inhibitor 
M2 activity 
inhibitor 
(adamantanes) 
- - 
Neurami-
nidase 
inhibitors 
(zanamavir, 
oseltamivir) 
Respiratory 
syncytialvirus 
F protein 
inhibitor 
(palivizumab) 
- 
siRNA 
Viral mRNA 
attachment blocker 
(ribavirin) 
- - 
Parainfluenza 
virus 
- - siRNA - - 
Adenovirus - - 
 
DNA synthesis 
inhibitor (cidofovir) 
Viral mRNA 
attachment blocker 
(ribavirin) 
- - 
Bocavirus - - - - 
- 
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1.4.3 Interferons 
 
In response to the presence of a virus infection, host cells produce interferons (IFN), 
which act by inhibiting protein synthesis and stimulating host defense mechanisms including 
cellular and humoral immune responses. Several studies have evaluated the efficacy and 
safety of intranasal recombinant IFN 2b in the prevention or treatment of HRV infections 
(Nichols et al., 2008). In these studies, only prophylactic use showed modest efficacy, and 
was ineffective against symptomatic HRV infection. In addition, prolonged use induced 
histological changes in the nose. 
1.4.4 Oral rehydration therapy 
 
In general, viral gastroenteritis is treated with counteracting the dehydration by 
correcting the fluid loss and electrolyte imbalance (Cheng et al., 2005, Gadewar and Fasano, 
2005). Mortality from acute diarrhea has decreased substantially due to worldwide 
campaigns of treatment with oral rehydration therapy. However, rehydration therapy does 
not shorten the diarrhea. Rehydration therapy encompasses two phases: a rapid oral 
rehydration phase, in which water and electrolytes are administered as oral rehydration 
solution (ORS) to replace existing losses, and a maintenance phase, which includes both 
replacement of ongoing fluid and electrolyte losses, and adequate dietary intake with normal 
foods appropriate to the age of the subject  (King et al., 2003). According to the guidelines of 
European Society for Paediatric Gastroenterology, Hepatology, and Nutrition, specific 
probiotics (mainly lactobacilli) with proven efficacy in viral diarrhea in children together with 
rehydration therapy may reduce duration and severity of diarrheal symptoms of acute 
gastroenteritis (Guarino et al., 2008).  
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2 CRITICAL HOST FACTORS IN VIRUS INFECTIONS  
 
The mucosal surfaces are the primary portals of entry for respiratory and gastrointestinal 
viruses.  Innate and adaptive immune responses are the most important defense mechanisms 
of the host in order to combat against virus infections. Responses may act directly on the 
virus, or indirectly on virus replication by altering or killing the infected cell.  Innate 
responses are unspecific and function early, and include physical, chemical, and 
microbiological barriers, as well as many elements of the immune system (monocytes, 
macrophages, natural killer (NK) cells, and virus-induced cytokines). Adaptive responses are 
highly specific, but the induction requires several days or weeks. In virus infections adaptive 
responses mainly depend on cytotoxic T cells and antibodies. Hallmark of adaptive immune 
response is the development of immunological memory. Although the host defense 
mechanisms involved in a particular viral infection vary depending on the virus, dose and 
portal of entry, critical host factors and immunological events in virus infections are 
summarized in Figure 2. 
2.1 INNATE IMMUNE SYSTEM 
 
The innate immune system is essential for the initial detection of invading viruses and 
subsequent activation of adaptive immunity. As the initial infection is established in 
epithelial cells lining the respiratory or gastrointestinal (GI) tract, epithelial cells as well as 
tissue resident macrophages and dendritic cells (DCs) detect the presence of invading viruses 
through pattern-recognition receptors (PRRs). There are three classes of receptors, which 
sense viral components: retinoic acid-inducible gene I like receptors (RLRs), toll-like 
receptors (TLRs), and nucleotide oligomerization domain-like receptors (NLRs) (Takeuchi 
and Akira, 2009, Rathinam and Fitzgerald, 2011). RLRs are cytoplasmic proteins sensing 
viral dsRNA. TLRs detect viral components outside of cells and in cytoplasmic vacuoles after 
phagocytosis or endocytosis. In humans TLR2, TLR3, TLR4, TLR7, and TLR9 are involved in 
the recognition of viral components. On the plasma membrane TLR2 and TLR4 recognize 
viral envelope proteins. TLR3, TLR7, and TLR9 are localized on cytoplasmic vesicles such as 
endosomes and the endoplasmic reticulum. TLR3 recognizes dsRNA, and TLR7 and TLR9 
recognize products of viral replication such as ssRNA and DNA with CpG motifs. NLRs are 
cytoplasmic proteins, which play a role in the production of mature interleukin (IL)-1β in 
response to the dsRNA stimulation. The recognition of viral components by these receptors 
initiates a cascade of signals that results in the production of type I IFNs (including IFN-α 
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and IFN-β), and proinflammatory cytokines. IFNs are key antiviral cytokines which play an 
essential role in both innate and adaptive immune responses to viruses (Iwasaki and 
Medzhitov, 2004). Inflammatory signals trigger also the production of chemokines by 
epithelial cells, macrophages, and DCs that attract more innate immune cells to the infection 
site.  The most important innate leukocytes involved in viral infection include the NK cells, 
which upon activation destroy virus infected cells by releasing small cytoplasmic granules of 
proteins called perforin and granzyme inducing cell apoptosis (Alter and Altfeld, 2006). 
Macrophages and DCs phagocytosize infected cells, and process viral antigens functioning as 
antigen-presenting cells (APCs), and initiating the adaptive immune response. 
2.2 ADAPTIVE IMMUNE SYSTEM 
 
Adaptive immune system acts against both viral particles and infected cells. The most 
important leukocytes of the adaptive immune system consist of T and B lymphocytes. T-cells 
are intimately involved in cell-mediated immune responses, whereas B cells play a major role 
in the humoral immune response. Adaptive immunity to a virus infection initiates as naive T 
lymphocytes recognize viral antigens from the APCs through specific receptors located on the 
surface of T-cells. APCs present viral antigens bound to the major histocompatibility complex 
(MHC) proteins. CD4+ T lymphocytes recognize antigen on the MHC class II receptors, 
expressed only on APCs. CD8+ T lymphocytes recognize antigen on the MHC class I 
receptors, expressed on all nucleated cells. Upon specific antigen recognition T-cells undergo 
clonal amplification and progressively acquire differentiated functions (Kidd, 2003, Izcue 
and Powrie, 2008). CD8+ T cells mature into cytotoxic T lymphocytes (CTL), which 
specifically kill pathogen-infected cells. CD4+ helper T cells (Th) mature into two major 
subsets of effectors based on their cytokine expression profiles. Th1 cells coordinate the host 
response to intracellular pathogens, and have a central role in phagocyte activation, which 
promotes viral killing (Soghoian and Streeck, 2010). Th2 cells promote humoral immunity 
leading to activation of B cells (plasma cells) and the release of antibodies (immunoglobulins, 
Ig) into blood and tissue fluids. Other subsets include T regulatory cells, which negatively 
control the T-cell responses by producing specific cytokines and Th17 cells, which regulate 
the cellular immune response to influenza infection. As B cells and T cells are activated and 
begin to replicate, some of their offspring will become long-lived memory cells.  
Immunological memory can be in the form of either passive short-term memory or active 
long-term memory. 
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2.2.1 Cytotoxic mechanisms 
 
Cytotoxic mechanisms are effective against virus infected cells. Once CTL has recognized 
viral antigen in a complex with the MHC I receptor, it migrates to the infection site. When an 
activated CTL contacts infected cells, it releases cytotoxins such as perforin, which form pores 
on the plasma membrane of a target cell, allowing ions, water and toxins to enter. The entry 
of protease granulysin induces the target cell to undergo apoptosis (Radoja et al., 2006).  CTL 
cytotoxic activity is particularly important in preventing the replication of viruses. CTLs also 
release antiviral substances such as IFN-γ (Kagi et al., 1994), which enhance, and promote 
proliferation, activation, and prolonged survival of T cells. 
2.2.2 Antibody responses 
 
The most important mechanisms against viral particles are antibodies.  After recognition 
of viral antigen on Th2 cells, B cells differentiate into plasma cells and begin to produce 
specific antibodies. Antibodies are produced against many epitopes on multiple virus 
proteins. A subset of these antibodies can block virus infection by neutralization, which 
inhibits virion binding to the receptors and uptake into cells, prevents uncoating of the viral 
genomes in endosomes, or cause aggregation of virus particles.  Alternatively, antibodies can 
be elicited by virion fragments, or by viral proteins that are released from dying, infected cells 
(Hangartner et al., 2006). Antibodies that bind to surface-accessible determinants have been 
shown to help to control certain virus infections by activating the complement system, 
augmenting phagocytosis and/or promoting antibody-dependent cellular cytotoxicity. The 
main antibody isotypes in the virus specific humoral immune response are IgA, IgM, and 
IgG.  For most viruses, specific IgA antibodies play a key role in clearing the virus from 
mucosal sites during primary and secondary infection (Russell 1999).  IgG and IgM 
antibodies are more predominant in viremic infections. Serum IgAs are also produced after 
influenza virus infection (Voeten et al., 1998, Rothbarth et al., 1999). 
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Figure 2. A schematic presentation of innate and adaptive immune responses during viral 
infection.  
REVIEW OF THE LITERATURE 
33 
 
3 PROBIOTICS IN THE PREVENTION OF RESPIRATORY AND 
GASTROINTESTINAL VIRUS INFECTIONS  
3.1 OVERVIEW OF PROBIOTICS  
 
According to WHO probiotics are live microorganisms, which administered in adequate 
amounts, confer a health benefit on the host (FAO/WHO, 2002). Probiotics must be able to 
survive in the GI tract and to proliferate in the gut, and be resistant to gastric juices and bile. 
In addition, they should exert benefits to the host through growth and/or activity in the 
human body. In order to confer health benefits, they should be non-pathogenic and non-
toxic, and provide protection against pathogenic micro-organisms by means of multiple 
mechanisms (FAO/WHO, 2001). In addition, probiotics should be lacking transferable 
antibiotic resistence.  Different bacterial strains of the same genus and species, verified also 
by genomic information, may exert completely different effects on the host. The most 
promising health effects of probiotics in human intervention studies include amelioration of 
acute diarrhea in children, reduction of the risk of RTIs, relief of children’s milk 
allergy/atopic dermatitis, and relief of irritable bowel syndrome (Wolvers et al., 2010, Aureli 
et al., 2011). Probiotics may exert their beneficial health effects by normalization of 
microbiota, modulation of immune response, and metabolic functions. They may also 
enhance the resilience of microbiota against detrimental outside factors. However, the 
molecular mechanisms behind the effects are largely unknown (Marco et al., 2006). The most 
commonly investigated and commercially available probiotic species are mainly lactic acid 
bacteria of Lactobacillus ssp. and Bifidobacterium ssp. In addition, several other species of 
the genus such as Propionibacterium, Streptococcus, Bacillus, Enterococcus, and yeasts are 
used. Lactobacillus rhamnosus GG (ATCC 53103) is one of the most extensively studied 
probiotic strains in humans and experimental studies (Figure 3). Since its isolation from an 
adult human in 1985, it has gained a safe history of use in food products since 1990. The 
strain provides excellent survival in and transient colonization of the GI tract, which is 
attributed to its adhesion capacity to the intestinal mucus and epithelial cells (Alander et al., 
1999, Saxelin et al., 2010). 
 
In the industry, probiotics are mainly incorporated into fermented foods (milk, cheese, 
yoghurt), but also in non-dairy products such as chocolate, cereals, and juices (Anal and 
Singh, 2007). Probiotic supplements are also available in different formulations such as 
capsules, sachets or tablets, and with and without prebiotics such as fructo- and galacto-
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oligosaccharides. Ingested probiotic strains do not become established members of the 
normal intestinal microbiota, but generally persist only for the period of consumption and for 
some months thereafter (Gueimonde et al., 2006, Corthésy et al., 2007). Probiotics must also 
retain their viability during storage, manufacturing process of the functional food, and transit 
through the stomach and small intestine. The concentration of probiotics in research trials 
and in commercial products varies significantly, and no international standards are available 
regarding the levels of required bacteria (Parvez et al., 2006). 
 
Probiotic bacteria are often a part of/members of the normal gastrointestinal microbiota, and 
therefore probiotic therapy is generally considered as safe (Boyle et al., 2006). However, 
probiotic therapy has raised potential safety concerns including systemic infections, toxic or 
metabolic effects on the GI tract, and the transfer of antibiotic resistance in the 
gastrointestinal microbiota (Sanders et al., 2010). In Finland, increased consumption of 
probiotic products containing L. rhamnosus GG has not resulted in significant increase in 
Lactobacillus bacteremia (Salminen et al., 2002). In addition, L. rhamnosus GG 
consumption is regarded as safe in immunocompromised HIV-infected patients (Salminen et 
al., 2004). In addition, clinical studies show that L. rhamnosus GG is safe treatment for 
neonates and infants (Isolauri et al., 1991, Van Niel et al., 2002, Grandy et al., 2010, 
Szajewska et al., 2011, Luoto et al., 2010). However, in rare cases, some studies have reported 
Lactobacillus septicaemia in children (Land et al., 2005), or in immunocompromised 
subjects (Kalima et al., 1996), and detrimental effects in subjects with hepatitis (Besselink et 
al., 2008). Moreover, the European Food Safety Authority has concluded that there are no 
specific safety concerns regarding Lactobacilllus, Bifidobacterium, or Propionibacterium 
strains as they have a long history of safe use in food (EFSA, 2011). However, it should be 
taken into consideration that the safety of probiotics has not been as systematically 
investigated as in drugs and the safety evaluation is partly based on long term experience. 
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Figure 3. The illustration of L. rhamnosus GG with electronic microscope. Adapted from 
Kankainen et al. 2009 (Kankainen et al., 2009).  
 
3.2 MECHANISMS OF ACTIONS OF PROBIOTICS IN VIRUS INFECTIONS 
 
Clinical and animal studies have demonstrated that specific probiotics are effective in 
viral infections, but the underlying mechanisms are not completely understood. Additionally, 
the strain to strain variation may be relatively large concerning strain properties and efficacy. 
Possible antiviral mechanisms of probiotics include 1) hindering the adsorption and, 2) cell 
internalization of the virus, 3) production of metabolites and substances with a direct 
antiviral effect, and 4) crosstalk (immunomodulation) with the cells in establishing the 
antiviral protection. The possible mechanisms by which probiotics may influence in virus 
infections are presented in Figure 4. 
  
REVIEW OF THE LITERATURE 
36 
 
 
 
Figure 4. Probiotics may prevent viral infections through several mechanisms. 
 
❶ Probiotic bacteria may bind directly to the virus and inhibit virus attachment to the host cell receptor. 
❷ Adhesion of probiotics on the epithelial surface may block viral attachment by steric hindrance, cover    
      receptor sites in a  non-specific manner, or by competing for specific carbohydrate receptors. 
❸Probiotics may induce mucosal regeneration: intestinal mucins may bind to viruses, and inhibit their 
      adherence to  epithelial cells and inhibit virus replication. 
❹ Probiotics also show direct antimicrobial activity against pathogens by producing antimicrobial substances. 
❺ Induction of low grade NO production and dehydrogenase production may have antiviral activities. 
❻ Probiotics promote normalization of mucosal barrier and increase integrity of mucosal cells. 
❼ Modulation of immune response through epithelial cells. 
❽ Modulation and activation of immune responses through macrophages and DCs. 
❾ Upon activation CD8+ T lymphocytes differentiate into CTLs, which destroy virus infected cells. 
❿ CD4+ T lymphocytes differentiate into Th1 and Th2 cells. 
⓫ Th1 activates phagocytes promoting virus killing. 
⓬ Th2 induce proliferation of B-cells, which travel to secondary lymphatic organs in mucosa associated  
       lymphoid tissue (MALT) and differentiate into Ig-producing plasma cells, which may migrate back to the   
       infection site. 
⓭ Secretory antibodies neutralize the virus. 
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3.2.1 Antagonisms to pathogens 
 
Respiratory and GI tract are covered by mucosal epithelial surfaces which are constantly 
exposed to numerous micro-organisms, and serve as primary ports of entry for most 
infectious viruses. Virus attachment to a host cell is the first essential step in the disease 
process, and therefore interruption of this attachment could be beneficial to the host. 
Probiotic bacteria may bind directly to the virus, and inhibit virus attachment to the host cell 
receptor. For instance, there is evidence that in vitro specific strains of lactobacilli and 
bifidobacteria are able to bind and inactivate RV (Salminen et al., 2010) and vesicular 
stomatitis virus (flu-like virus) (Botić et al., 2007). In addition, adhesion of probiotics on the 
epithelial surface (Juntunen et al., 2001, Ouwehand et al., 2001, Ouwehand et al., 2002) may 
block viral attachment by steric hindrance, cover receptor sites in a non-specific manner, or 
inhibit binding of a virus to specific carbohydrate receptors. Luminal secretions (mucus, 
glycolipids, protective peptides) and antimicrobial peptides (defensins) may also protect 
epithelial cells from virus infections.  Intestinal mucins may bind to viruses through specific 
mucin-bacterial/viral interaction, inhibit their adherence to the epithelial cells (Deplancke 
and Gaskins, 2001), and inhibit virus replication (Yolken et al., 1994). Probiotics may induce 
mucosal regeneration by increasing mitose rate in the small intestine, increasing the 
numbers of cells in the villi (Banasaz et al., 2002, Pipenbaher et al., 2009), and promoting 
intestinal epithelial homeostasis via soluble proteins (Yan et al., 2007).  Probiotics also show 
direct antimicrobial activity against pathogens by producing antimicrobial substances such as 
organic acids, hydrogen peroxide, diacetyl, short chain fatty acids, biosurfactants, and 
bacteriocins (Servin, 2004). In experimental studies in epithelial cells and macrophages 
metabolic products of specific lactobacilli and bifidobacteria prevented vesicular stomatitis 
virus infection in a strain specific manner (Botić et al., 2007), and metabolites of yoghurts 
showed antiviral activity inhibiting influenza virus and enterovirus replication (Choi et al., 
2009). Supernatants of L. plantarum Probio-38 and L. salivarius Probio-37 inhibited 
cytopathic effect of Transmissible Gastroenteritis Coronavirus (Kumar et al., 2010). Nitric 
oxide (NO) has also been recognized as a compound with antiviral properties (Kleinert et al., 
2004, Xu et al., 2006). Induction of low-level synthesis of NO may be involved in the 
protective actions of probiotics against viruses in the GI tract or respiratory cells as shown in 
rat and in vitro models (Korhonen et al., 2001, Sobko et al., 2006, Ivec et al., 2007, 
Pipenbaher et al., 2009, Maragkoudakis et al., 2010). It is widely known that the intestinal 
permeability increases in gastrointestinal virus infections, as viruses attach to cell receptors 
below the tight junctions on the basolateral membrane, thus modifying tight junctions and 
disturbing the barrier (Guttman and Finlay, 2009). One possible mechanism of probiotics is 
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the promotion of gut defense barrier by normalizing increased permeability and disturbed 
gut microecology (Isolauri et al., 1993, Otte and Podolsky, 2004). 
3.2.2 Immunomodulation  
 
An effectively functioning immune system is important for the maintenance of 
physiological integrity and health. The immune system provides defence against infections 
caused by pathogenic microorganisms.  It also modulates our health and well-being in many 
ways sometimes by up- or downregulating the defence system.  An optimally functioning 
immune system is fundamental for protection against infectious diseases. Induction of 
antiviral cytokines such as IFNs, as well as proinflammatory cytokines and chemokines upon 
antigen recognition in epithelial cells or underlying effector cells (macrophages, DCs, 
neutrophils) play a key role in virus infections by initiating cell mediated viral elimination 
and adaptive immune responses. One possible probiotic mechanism against virus infections 
could be the stimulation of the gut immune system (Schiffrin and Blum, 2002). In the gut 
epithelial cells and/or APCs, probiotics are recognised by TLRs (Miettinen et al., 1998, 
Vinderola et al., 2005,Foligne et al., 2007, Miettinen et al., 2008). Probiotics may therefore 
modulate cytokine expression patterns through epithelial cells (O'Hara et al., 2006), and 
through underlying professional APCs, such as macrophages and DCs (Miettinen et al., 2000, 
Veckman et al., 2003, Veckman et al., 2004, Latvala et al., 2009, Latvala et al., 2011, Weiss et 
al., 2011). In murine DCs L. acidophilus NCFM and L. acidophilus X37 were able to trigger 
the expression of viral defense genes (IFN-β, IL-12, IL-10) (Weiss et al., 2010). Also 
stimulation of human macrophages or DCs with specific probiotics including L. rhamnosus 
GG, have induced proinflammatory cytokine (tumor necrosis factor (TNF)-α, IL-1β, IL-6, and 
IFN-γ) and chemokine (CCL2, CCL3, CCL5, CCL7, CCL20 and CXCL8) production 
(Miettinen et al., 2000, Veckman et al., 2003, Latvala et al., 2009). Indeed, many 
experimental studies in vitro show that certain strains of probiotics are capable of providing 
protection against virus infections by stimulating antiviral, cytokine, and chemokine 
responses in respiratory and gastrointestinal epithelial cells, or immune cells (Table 4). In 
addition, oral administration of lactobacilli in mice may affect respiratory virus infections 
(such as influenza) by reducing virus titer in the lungs, and increasing survival rate of the 
animals via stimulating innate immune responses (Table 5). There is also evidence that 
intranasal administration of probiotics is able to protect against respiratory virus infection by 
stimulating innate immune responses directly in the respiratory epithelium (Hori et al., 2001, 
Harata et al., 2010, Izumo et al., 2010, Harata et al., 2011, Gabryszewski et al., 2011, Youn et 
al., 2012).  
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Oral ingestion of viral antigens also induces in the gut local IgA synthesis. After antigenic 
stimulation in the Peyer’s patches, T and B lymphocytes activate and travel via blood 
circulation to secondary lymphatic organs in the distal mucosal effector sites of the GI and 
respiratory tracts (so-called mucosa-associated lymphoid tissue, MALT), where B cells 
differentiate into Ig-producing plasma cells. By this mechanism orally-ingested probiotic 
bacteria may initiate an immune response in the gut, which then leads to enhanced responses 
at other mucosal surfaces. Data from animal studies indicate that several specific lactobacilli 
and bifidobacteria provide protection against respiratory and gastrointestinal virus infections 
by inducing the synthesis of virus-specific Igs in intestinal and respiratory secretions, in 
Peyer’s patch cells and in serum (Table 6).  
 
Table 4. Effects of probiotic bacteria on innate immune responses against gastrointestinal 
and respiratory virus infections in vitro.  
Probiotic strains Virus  Model/Study design Main findings Reference 
L. acidophilus NCFM 
L. rhamnosus GG  
Porcine 
RV, HRV 
Wa 
In vitro: 
Probiotic incubation of 
procine epithelial cells 
(IPEC-J2) before and 
after infection 
Virus infection ↔ 
Effects wth L.GG:   
After RV infection mucin 
secretion and IL-6 ↓ 
Effects with LA 
treatment: 
Prior RV infection,RV 
replication and  IL-6 ↑   
Liu  et al. 2010 
L. plantarum 299v  Bovine RV  In vitro: RV infection ↓ Thompson et 
al. 2010 Probiotic incubation of 
primary bovine 
intestinal epithelial cells 
before infection 
IFN-α ↑, TRL3 ↑ 
L.paracasei/rhamnosus 
Q85 
L. paracasei A14 
L. paracasei F19 
B. longum Q46 
Vesicular 
stomatitis 
virus  
In vitro: 
Preicubation of pig 
alveolar macrophages 
with bacteria before 
infection 
Strain spesific effects: 
Cell survival against virus 
infection ↑ 
NO production  ↑ 
IL- 6 , INF-gamma ↑ 
Ivec et al. 2007 
L. pentosus S-PT84  Sendai 
virus 
Ex vivo: 
Oral ingestion of 
probiotic in diet 14d 
before experiment in 
mice splenocytes and 
plasmacytoid DCs 
 IFN-α  ↑ Izumo et al. 
2011 
↑ = increase; ↓ = decrease; ↔ = no effect 
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Several studies also suggest that specific probiotics may enhance the immunogenicity of viral 
vaccines in healthy human subjects. Orally administered L. casei strain GG improved the 
immunogenicity of RV vaccine in children by increasing RV-specific IgM secreting cells, and 
enhancing significantly IgM and IgA seroconversion (Isolauri et al., 1995). Vaccination 
against diphtheria and tetanus toxoids, poliomyelitis virus, Haemophilus influenzae, and 
Bordetella pertussis showed that infants harboring detectable levels of B. longum infantis in 
the intestine had two months after vaccination higher anti-poliovirus IgA titers (Mullie et al., 
2004). Moreover, in healthy adults L. rhamnosus GG or L. acidophilus CRL431 increased 
poliovirus vaccine induced neutralizing antibody titers, and increased in serum the formation 
of poliovirus-specific IgA and IgG (De Vrese et al., 2005). L. rhamnosus GG was also effective 
in inducing protective immune response against H3N2 strain in influenza virus vaccine 
(Davidson et al., 2011). Moreover, L. fermentum CECT5716 ingestion in adults resulted in 
lower influenza-like illness, increased proportion of NK cells in blood, significantly higher 
TNF-α, and increased anti-influenza specific IgA, and IgM after influenza vaccination 
(Olivares et al., 2007). Consumption of B. animalis subsp. lactis Bb12 or L. paracasei ssp. 
paracasei L. casei 431431 also showed significantly greater increase in influenza virus 
vaccine-specific IgG antibodies in plasma and secretory IgA in saliva (Rizzardini et al., 2012). 
In the elderly the consumption of fermented yoghurt with L. casei DN-114 001, increased 
significantly influenza -specific antibody titers after influenza vaccination, especially against 
influenza B virus (Boge et al., 2009). These studies suggest that orally-ingested lactobacilli 
and bifidobacteria have an adjuvant-like effect on the humoral responses. 
 
In summary, based on animal and experimental studies in vitro, specific probiotics may 
mediate their health effects against viral infections with their ability to exclude viruses, 
strengthen the tight junctions between enterocytes, produce antimicrobial and potentially 
antiviral substances, and stimulate host-cell immune defenses. In addition, specific 
probiotics enhance the immunogenicity of vaccines by stimulating humoral responses. 
However, the effects of probiotics seem to be highly strain specific.  
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Table 5. Effects of probiotic bacteria on innate immune responses against respiratory virus 
infections in animal experiments.  
Probiotic strains Virus  Model/Study design Main findings Reference 
L. casei Shirota  IFV A⁄PR⁄8⁄34 
(H1N1) 
BALB/c mice, 
n=14/group, 
intranasal 
administration 3x 
daily for 3d before 
infection 
IL- 12, IFN-γ, TNF-α  in MLN 
cells ↑ 
Virus titres in nasal wash ↓ 
Mice survival rate ↑ 
Hori et al. 
2001 
L. casei Shirota  IFV A⁄PR⁄8⁄34 
(H1N1) 
BALB/c mice, 
n=5/group, oral 
administration 
5x/week for 3 weeks 
before infection 
Mice survival rate ↑ 
Pulmonary NK cell activity ↑ 
IL-12 production  
by MLN cells ↑ 
Viral titres in nasal 
washings↓ 
Yasui et al. 
2004 
L. plantarum L-137 IFV 
A/FM1/47 
(H1N1) 
C57BL/6 mice, 
n=6/group, 
intragastric 
administration daily 
7d before and 6d 
after infection 
Viral titers in the lung ↓ 
IFN-β in sera ↑ 
Maeda et al. 
2009 
L. pentosus S-PT84  IFV A⁄PR⁄8⁄34 
(H1N1) 
BALB/c mice, n=11-
12/group, intranasal 
administration of S-
PT84 1x daily for 3d 
Mice survival rate ↑ 
(especially orally) 
virus titter in BALF ↓ 
IL-12,  IFN-γ in MLN cells ↑ 
IL-12 ,I FN-α in BALF ↑ 
NK cell activity  ↑ 
Izumo et al. 
2010 
L. gasseri TMC0356 
L. rhamnosus GG  
IFV A⁄PR⁄8⁄34 
(H1N1) 
BALB/c mice, 
n=13/group, oral 
administration daily 
for 19d 
Effects with both bacteria: 
Clinical symptom scores ↓ 
Pulmonary virus titres ↓ 
Kawase et 
al. 2010 
    Effects with L.gasseri: 
Peyer's patches: mRNA IL-12, 
IL-15, IL-21 ↑ 
Lungs: mRNA IFN-γ, TNF, IL-
12, perforin-1 ↑ 
Kawase et 
al. 2012 
L. plantarum 05AM2 
L. plantarum 06TCa8 
L. paracasei ssp. 
paracasei 06TCa19 
L. paracasei ssp. 
paracasei 06TCa22 
L. paracasei ssp. tolerans 
06TCa39 
L. plantarum 06TCa40 
L. paracasei ssp. 
paracasei 06TCa43 
L. plantarum 06CC2 
L. delbrueckii ssp. lactis 
06TC3 
L. plantarum 06CC9  
IFV A⁄PR⁄8⁄34 
(H1N1) 
BALB/c mice, n=5-
10/group, oral 
administration 
2xdaily for 10d 
starting 2d before 
infection 
Effects with L.plantarum 
06CC2: 
Protected body weight loss 
of infected mice 
Virus yields in the lungs ↓ 
Mice survival ↑ 
No.of macrophages and 
neutrophils in BALF ↓ 
TNF-α in BALF ↓ 
INF-α, IL-12, IFN-γ,  
NK cell activity ↑  
mRNA IL-12 receptor, IFN-γ 
in Peyer's patches ↑ 
Takeda et al. 
2011 
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Table 5. Continued 
 
    
Probiotic strains Virus  Model/Study design Main findings Reference 
L. gasseri TMC0356 
L. rhamnosus GG 
IFV A⁄PR⁄8⁄34 
(H1N1) 
BALB/c mice, n=13-
19/group, 
intranasally 
administered 3x 
daily for 3d 
L. gasseri TMC0356: 
Morbidity ↓ 
Survival rate of mice↑  
mRNA  IL-1β, TNF, 
IL-10, MCP-1 ↑ 
Harata et al. 
2010 
    L. rhamnosus GG: 
Accumulated symptoms ↓ 
Survival rate of mice ↑ 
mRNA IL-1β, TNF,IL-10, and 
MCP-1↑ 
Harata et al. 
2011 
L. fermentum-1 
L. brevis-2  
IFV 
A/NWS/33 
(H1N1) 
BALB/c mice, 
n=10/group, 
intranasal or oral 
administration for 
21d before infection 
Mice survival ↑ 
Virus titer ↓ 
Lung IgA and IL-12 ↑ 
Lung TNF-α and IL-6 ↓ 
Lung IFN-γ ↔ 
Youn et al. 
2012 
B. longum BB536 IFV 
A/PR/8/34 
(H1N1) 
BALB/c mice, 
oral administration 
daily for 2 weeks 
before infection 
Symptom score ↓ 
Loss of body weight ↓ 
Lung virus titer ↓ 
Lung IL-10, IL-12 ↔ 
Lung IL-6, IFN-γ (↓) 
Iwabuchi et al. 
2011 
L. casei Shirota 
L.  fermentum  
Murine 
cytomegalo- 
virus  
ICR-mice, N/A Effects with L. casei: 
Mice survival ↑ 
Virus titters ↓ 
NK cell activity ↑ 
Ohashi et al. 
1989 
L. plantarum NCIMB 8826 
L. reuteri  F275  
Pneumonia 
virus of mice  
J3666 
BALB/c and C57BL/6 
mice,n=5-10/group, 
intranasal 
inoculation 2 weekly 
doses 2 weeks 
before infection  
Protection against virus 
infection ↑ 
Granulocyte recruitment ↓ 
CXCL10, CXCL1, CCL2,TNF↓ 
Virus recovery ↓  
Gabryszewski 
et al. 2011 
IFV = influenza virus; ↑ = increase; ↓ = decrease; ↔ = no effect; MLN = mediastinal lymph node  
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Table 6. Reported effects of probiotic bacteria on antibody responses against 
gastrointestinal and respiratory virus infections in animal experiments.  
Probiotic strains Virus  Model Main findins Reference 
B. bifidum ATCC 15696 Murine RV 
EDIM-5099 
BALB/c mice, n=15-
19/group, orally 
administered in 
saline 5d before and 
23d after infection 
RV antigen shedding ↓ Duffy et al. 
1994 Onset of acute diarrhea ↓ 
Serum RV IgG antibody 
responses ↔  
B. breve YIT4064  SA-11 RV  Oral administration 
of bacteria in mice 
Protection against 
RV diarrhea ↑ 
Yasui et al. 
1995 
anti-RV IgA in milk 
and feces ↑ 
Combination of: Rhesus RV BALB/c mice, n=3-
8/group, 1 dose 
weekly orally 
administered up to 7 
weeks after infection 
Bifidobacteria alone or with 
prebiotics: 
Qiao et al. 
2002 
B. bifidum ATCC 15696 Onset of diarrhea ↓ 
B. infantis ATCC 15697 Recovery of diarrhea ↑ 
with or without prebiotics RV-specific IgA in feces and in 
serum  ↑ 
Combination of: 
L. acidophilus strain NCFM 
L. reuteri strain ATCC 23273 
Human RV 
Wa strain 
and RV 
vaccination 
Gnotobiotic pigs, 
n=4-10/group,  oral 
administration in 
peptone water with 
gradual 
concentrations 2x 
before infection and 
3x after infection 
Total intestinal IgA  cell 
responses ↑ 
Zhang et 
al. 2008a 
Total serum IgM, intestinal 
IgM, IgG↑ 
Zhang et 
al. 2008b 
RV shedding or diarrhea ↔  
RV-specific IFN-γ producing 
CD8+ T cell responses in ileum 
and spleen ↑ 
 
IgA and IgG antibody-secreting 
cell responses in ileum ↑ 
 
Serum IgM, IgA and IgG 
antibody and RV neutralizing 
antibody titers ↑ 
  
B. breve YIT4064  IFV 
A⁄PR⁄8⁄34 
(H1N1) 
BALB/c mice, n=9-
10/group, oral 
administration in 
food 15 weeks 
before infection 
Protection against virus 
infection ↑ 
Yasui et al.  
1999 
Serum anti-IFV IgG ↑ 
L. pentosus b240  IFV 
A⁄PR⁄8⁄34 
(H1N1) 
BALB/c/Cr Slc (SPF), 
n=10/group, 
administration daily 
by gavage all 
experiment (1mo) 
Virus titer ↓ Kobayashi 
et al. 2011 Anti-IFV IgA, IgG titers in BALF 
and plasma on day 7 ↑ 
L. delbrueckii ssp. 
Bulgaricus 
OLL1073R-1 and its 
exopolysaccharides 
IFV 
A⁄PR⁄8⁄34 
(H1N1) 
BALB/c mice, oral 
administration for 
21d prior infection 
In both groups: 
Mice survival ↑ 
Virus titer ↓ 
Anti-IFV IgA, IgG1 in BAL ↑ 
NK cell activity ↑ 
Nagai et al. 
2011 
↑ = increase; ↓ = decrease; ↔ = no effect; IFV = influenza virus; BALF = bronchoalveolar lavage fluid   
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3.3 HEALTH EFFECTS OF PROBIOTICS IN VIRUS INFECTIONS 
3.3.1 Animal experiments 
 
Animal experiments provide insight of clinical effects of probiotics against certain virus 
infections. Studies of respiratory virus infections in mice provide strong evidence that certain 
strains of lactobacilli and bifidobacteria protect from virus infection by reducing virus titers 
in the lungs or nasal washings and RTI symptoms, or increasing body weight during infection 
and mice survival  (Ohashi et al., 1989, Yasui et al., 1995, Yasui et al., 1999, Hori et al., 2001, 
Yasui et al., 2004, Maeda et al., 2009, Harata et al., 2010, Izumo et al., 2010, Kawase et al., 
2010, Gabryszewski et al., 2011, Izumo et al., 2011, Harata et al., 2011, Kobayashi et al., 2011, 
Nagai et al., 2011, Takeda et al., 2011, Kawase et al., 2012, Youn et al., 2012,). There are also 
few studies concerning gastrointestinal virus infections in animals, which concentrate in RV 
infections. Specific probiotics have reduced RV diarrhea occurrence, duration, and severity, 
and reduced RV shedding in the feces or viral load in the intestine (Duffy et al., 1994, Guérin-
Danan et al., 2001, Qiao et al., 2002, Pant et al., 2007, Moreno Munoz et al., 2011). In 
addition, some lactobacilli have reduced RV induced histological changes in the intestine 
(Guérin-Danan et al., 2001, Pant et al., 2007, Preidis et al., 2012).  
3.3.2 Clinical trials 
 
Human intervention studies have demonstrated that specific probiotics may be able to 
shorten the duration or reduce the risk of certain viral infections.  Several trials in children 
address the effects of probiotics in the prevention of respiratory infections. L. rhamnosus GG 
(Hatakka et al., 2001, Hatakka, 2007), L. casei DN114001 (Cobo Sanz et al., 2006), B. 
animalis subsp. lactis Bb12 (Taipale et al., 2011), and a combination of L. rhamnosus GG, L. 
rhamnosus Lc705, B. breve Bb99 and P. freudenreichii ssp. shermanii JS (Hatakka, 2007), 
and a combination of L. rhamnosus GG and Bifidobacterium lactis Bb12 (Rautava et al., 
2009) have reduced the incidence or risk of respiratory infections. Treatment with L. 
rhamnosus GG (Hatakka et al., 2001) or a combination of L. reuteri SD112 and B. lactis Bb12 
(Weizman et al., 2005) resulted in fewer days of absence from day care due to illness.  In 
addition, probiotics such as Lactobacillus have reduced the incidence of otitis media in 
healthy children and in newborns (Niittynen et al.2012). However, the viral etiology of RTIs 
was investigated only in one study (Hatakka, 2007).  
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The strongest health benefits of probiotics in virus infections are demonstrated with L. 
rhamnosus GG in RV gastroenteritis in infants and in children (Table 7). These studies show 
that L. rhamnosus GG is able to shorten RV induced diarrheal phase/duration of diarrhea 
(Isolauri et al., 1991, Kaila et al., 1992, Isolauri et al., 1994, Majamaa et al., 1995, Guarino et 
al., 1997, Shornikova et al., 1997c, Guandalini et al., 2000), which was also shown in meta-
analysis (Szajewska et al., 2007). According to another meta-analysis, L. rhamnosus GG 
reduces the risk of symptomatic RV gastroenteritis (Szajewska et al., 2011). L. rhamnosus GG 
reduces also the number of RV infections (Salazar-Lindo et al., 2004). In a study conducted 
in India, however, L. rhamnosus GG did not have and impact on the duration of RV diarrhea, 
vomiting, or in the length of hospital stay (Basu et al., 2007). In undernourished Peruvian 
children, L. rhamnosus GG did not reduce the number of RV induced diarrhea. L. rhamnosus 
GG was also ineffective in preventing nosocomial RV infections (Mastretta et al., 2002). 
Similar effects were seen in a study by Szajewska and others 2001, although in that study the 
risk of RV gastroenteritis reduced significantly (Szajewska et al., 2001).  L. rhamnosus GG 
promotes recovery from RV diarrhea possibly via augmentation of the local immune defense 
by enhancing nonspecific humoral response (IgG, IgA, and IgM -secreting cell numbers) 
during the acute phase of RV infection (Kaila et al., 1992).  Furthermore L. rhamnosus GG 
promotes the development of RV specific IgA response, which may be relevant in protection 
against reinfections (Kaila et al., 1992, Majamaa et al., 1995, Kaila et al., 1995). Probiotic 
properties may alter in production processes, and thus the ability of L. rhamnosus GG to 
counteract diarrhea can be associated with the production method or food matrix as 
demonstrated by Grześkowiak et al. 2011 (Grześkowiak et al., 2011).  
  
Other Lactobacillus and Bifidobacterium strains have been studied in the treatment of RV 
gastroenteritis in children and infants as well (Table 8). L. reuteri in particular, has been 
effective in shortening the duration of RV diarrhea and number of days of illness (Shornikova 
et al., 1997a, Shornikova et al., 1997b).  L. sporogenes shortened the duration of RV diarrhea 
(Chandra, 2002) L. rhamnosus 35 reduced significantly fecal RV concentration (Fang et al., 
2009). Although L. paracasei strain ST11 had a clinically significant benefit in the 
management of non-RV-induced diarrhea, ST11 treatment against severe RV diarrhea was 
ineffective (Sarker et al., 2005). Children with RV infection received either B. Bb12 alone or 
together with Streptococcus thermophilus had less RV infections when measured by RV 
specific IgA concentration in the saliva (Phuapradit et al., 1999). Reduction of diarrhea 
duration in infants was also seen when S. boulardii was given to children within 72 hours 
after the onset of acute diarrhea although the number of RV infections were similar between 
groups (Corrêa et al., 2011). 
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Overall, studies conducted with bacterial combinations are also promising. A combination of 
L. rhamnosus strains, or L. rhamnosus 19070-2 and L. reuteri DSM 12246, or L. acidophilus, 
L. rhamnosus, B. longum and S. boulardii significantly reduced RV diarrhea and parenteral 
dehydration, consistency of feces, or duration of fever (Rosenfeldt et al., 2002, Szymanski et 
al., 2006, Grandy et al., 2010). Supplementation of infant formula with B. bifidum and S. 
thermophilus reduced significantly the incidence of acute RV diarrhea and RV shedding 
(Saavedra et al., 1994). Therapy with probiotic mixture VSL#3 (L. acidophilus, L. paracasei, 
L. bulgaricus, L. plantarum, B. breve, B. infantis, B. longum, S. thermophilus) resulted in 
earlier recovery and reduced frequency of ORS administration during RV diarrhea (Dubey et 
al., 2008). In another study probiotic product containing S. faecalis T-110, Clostridium 
butyricum TO-A, Bacillus mesentericus TO-A, and L. sporogenes reduced the  number of  RV 
episodes,  mean duration of diarrhea, degree of dehydration, duration and volume of ORS 
therapy and intravenous fluid therapy, and duration of RV shedding (Narayanappa, 2008). 
However, therapy of L. casei together with L. acidophilus, or S. boulardii alone did not affect 
the number of stools between RV negative and positive children, but significantly reduced the 
number of daily stools, diarrhea duration, and vomiting (Gaón et al., 2003).  
 
In summary, animal experiments have shown that certain strains of probiotics provide 
protection against respiratory and gastrointestinal viruses. In clinical studies, probiotics 
seem to be beneficial in the treatment and prevention of respiratory virus infections, 
although viral etiology has not been investigated. The strongest evidence concerning the 
treatment of RV gastroenteritis is attributed to L. rhamnosus GG, which seems to promote 
also humoral RV specific response. Combinations of several bacteria may ameriolate 
symptoms or reduce virus shedding as well.   
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Table 7. The reported effects of L. rhamnosus GG on RV infections in clinical interventions.  
Subjects  
Design and 
duration 
Probiotic 
supplementation  
Main findings: 
probiotic vs. placebo Reference 
Children aged 4-45 mo with 
acute gastroenteritis (n=71) 
RPC L. casei ssp. GG  
fermented milk 
10
10-11
 colony 
forming unit (cfu) , 
or 1x dose freeze 
dried powder, or 
placebo  2x daily  
for 5d on recovery 
from RV diarrhea 
L. casei ssp. GG  
fermented milk or 
powder: 
Diarrhea duration ↓ 
Number of RV in feces ↔ 
Isolauri et 
al. 1991 
Children aged 7-33 mo with 
acute gastroenteritis(n=44) 
RDBPC L. rhamnosus GG 
(10
10
-10
11
 cfu) in 
fermented milk and 
placebo, 2x daily for 
5d 
Diarrhea duration ↓ 
Nonspecific humoral 
response during the acute 
phase  infection ↑ 
IgG, IgA, and IgM Ig-
secreting cell numbers ↑ 
At convalescence, 
majority in L. GG  group 
developed RV IgA specific 
cell response  
Kaila et 
al.1992 
Children  aged 5-28 mo with 
acute RV diarrhea (n=42) 
RPC L. casei  GG 
(10
10
 cfu) or control 
group, oral 
administration 2x 
daily for 5d 
RV diarrhea duration ↓ Isolauri et 
al.  1994 
Children aged <4 years with 
acute gastroenteritis (n=41)  
RDBPC Inactive or live L. 
casei GG 2x daily  
for 5d 
Live L.GG: 
RV serum IgA  antibody 
responses ↑ 
Kaila et al. 
1995 
Children aged 6-35 mo 
(n=49) 
RCT L. casei ssp. casei 
GG , L. casei ssp. 
rhamnosus, or 
combination of 
Streptococcus 
thermophilus/L. 
delbruckii ssp. 
bulgaricus 2x daily 
for 5d 
Effects with all bacteria: 
Mean duration 
of diarrhea ↓ 
L.GG therapy:  
Antibody secreting cell IgA  
to RV ↑ 
Serum IgA  at 
convalescent stage ↑ 
Majamaa et 
al. 1995 
Children  aged 3-36 mo with 
mild diarrhea (n=100)  
RPC ORS or ORS+ L. casei 
strain GG 
 (3 ×10
9
  cfu) in milk 
2x daily for 5d 
Diarrhea duration ↓ 
RV shedding in stools ↓ 
Guarino et 
al. 1997 
Children aged 1- 36 mo with  
acute diarrhea (n=123) 
RPC ORS +L. GG 5x10
9
 
cfu or placebo 2x 
daily for 5d 
RV diarrhea duration ↓ 
Cumulative number of 
diarrhea stools ↓ 
Shornikova 
et al.  1997c 
 
Undernourished children 
aged 6-24 mo (n=200)  
RDBPC, 15 
mo 
L. rhamnosus GG 
(10
10
 cells ) or 
placebo in capsules 
mixed with liquid 
gelatin 6d a week 
Incidence of diarrhea ↓ 
(especially in 18- 29-mo 
age group) 
ADV in stools ↓ 
Other pathogens ↔ 
Oberhel-
man et al.  
1999 
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Table 7. Continued 
    
Subjects  
Design and 
duration 
Probiotic 
supplementation  
Main findings: 
probiotic vs. placebo Reference 
Children aged 
1 mo-3 years with acute-
onset diarrhea (n=140) 
RDBPC ORS+ L.rhamnosus 
GG (10
10
 cfu) or 
placebo 
administered first 4-
6h  
Diarrhea duration ↓ 
RV diarrhea duration ↓ 
Guandalini 
et al.  2000 
Hospitalized  children  
aged 1-36 mo (n=81) 
RDBPC L.rhamnosus GG 
 (6×10
9
 cfu) or 
placebo orally 2x 
daily for the 
duration of hospital 
stay 
Risk of RV 
gastroenteritis ↓ 
No. of RV  in stool ↔ 
Szajweska 
et al. 2001 
Hospitalized children aged 
1-18 mo for common 
infections (n=220)  
RDBPC, 17 
mo 
Capsules of 
L.rhamnosus GG 
(10
10
) or placebo 
daily during hospital  
No. of RV infections ↔ Mastretta 
et al.  2002 
Infants (male) aged  
3–36 mo with acute watery 
diarrhea (n=89) 
RDBPC L. casei  GG (10
9
 
cfu/ml) or placebo 
in milk powder in 
water after ORS 
therapy 
Diarrhea duration ↔ 
RV in stool ↓ 
Salazar-
Lindo et al.  
2004 
Young children under  
2 years with acute 
watery diarrhea (n=662)  
RDBPC, 12 
mo 
L.rhamnosus GG 
powder (10
6
 cells) 
dissolved in ORS or 
ORS alone 2x daily 
for at least 7d 
Daily frequency or 
duration of  RV 
diarrhea/vomiting ↔ 
Length of hospital stay ↔ 
Basu et al.  
2007 
Young children (n=988) Meta-
analysis: 8 
RCT 
L.rhamnosus GG RV diarrhea duration ↓ 
Risk of diarrhea ↓ 
Duration of 
 hospitalization ↓ 
Szajewska 
et al. 2007 
Hospitalized children  aged  
1 mo-18 years (n=1902) 
Meta-
analysis: 3 
RCT 
L.rhamnosus GG or 
placebo/or no 
intervention 
Rates of diarrhea ↓ 
Symptomatic RV 
gastroenteritis ↓ 
Szajweska 
et al.  2011 
RDBPC = randomized double-blind placebo-controlled; RPC = randomized placebo-controlled; RCT = 
randomized clinical trial; mo = months; ↑ = increase; ↓ = decrease; ↔ = no effect   
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Table 8. The reported effects of other bacteria on RV infections in clinical interventions.  
Subjects  
Design and 
duration 
Probiotic 
supplementation  
Main findings: 
probiotic vs. placebo Reference 
Hospitalized infants aged 5-
24  mo (n=55) 
DBPC, 17 mo B. bifidum and S. 
thermophilus (10
8
 cfu) 
in formula or standard 
infant formula 
Acute diarrhea 
incidence ↓ 
Stool RV shedding ↓ 
Saavedra et 
al. 1994 
Children aged 6-36 mo with 
acute diarrhea (n=66) 
RDBPC, 6mo L. reuteri (10
7
 or 10
10
-
10
11
 cfu) or placebo in 
capsules mixed with 
breast milk/infant 
formula  daily up to 5d 
Subjects receiving larger 
dosage: 
Duration of RV watery 
diarrhea ↓ 
Watery diarrhea after 
second day ↓ 
Serum RV IgG ↔ 
Shornikova 
et al.  1997a 
Children aged 6-36 mo with 
diarrhea (n=40) 
RDPC L. reuteri  10
10
-10
11
 
cfu, or placebo 1xdaily 
for 5d 
Duration of watery 
diarrhea ↓ 
Duration of RV 
associated diarrhea ↔, 
Fecal RV IgA ↔ 
Shornikova 
et al.  1997b 
 
Children aged 6-36 mo 
(n=175) 
8 mo B.Bb12 alone or 
together with 
S.thermophilus 
In both groups: 
Protection against RV ↑ 
Phuapradit 
et al.  1999 
Healthy newborns (n=94) RPC, 12 mo L. sporogenes (10
10
 
cells) or placebo 
mixed in sterile water, 
dosing daily for 12 mo 
Episodes of RV  
diarrhea ↓ 
No. of days of illness ↓ 
Duration of  diarrhea 
episodes ↓ 
Chandra et 
al. 2002 
Day care children aged 9-44 
mo with acute diarrhea 
(n=33) 
RDBPC, 6 mo Mixture of lyophilized 
L .rhamnosus 19070-2 
and L. reuteri DSM 
12246 (10
10
 cfu each) 
or placebo, dosing 2x 
daily for 5d 
Mean duration of 
diarrhea after 
intervention  ↓ 
Recovery  from diarrhea 
after early treatment ↑ 
Consistency of stools 
after treatment ↑ 
Rosenfeldt 
et al. 2002 
Children aged 6-24 mo with 
persistent diarrhea (n=89) 
DBPC L. casei and L. 
acidophillus strains 
CERELA (10
10
-10
12
 
cfu), S. boulardii in 
milk, or placebo for 2x 
daily for 5d 
Effects with both 
bacteria: 
No. of depositions,  
diarrheal duration, 
vomiting ↓ 
RV infections ↔ 
Gaón et al.  
2003 
Boys aged 4-24 mo with 
acute watery diarrhea 
(n=230)  
RPBPC, 24mo L. paracasei strain 
ST11 (5 x10
9
 cfu) and 
placebo, dosing 2x 
daily for 5d + ORS and 
continued feeding 
Severe RV diarrhea ↔ 
Children with less 
severe non-RV diarrhea: 
Cumulative stool 
output, stool frequency,  
and ORS intake ↓ 
Diarrhea resolvement 
after 6d ↑ 
Sarker et al. 
2005 
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Table 8. Continued 
    
Subjects  
Design and 
duration 
Probiotic 
supplementation  
Main findings: 
probiotic vs. placebo Reference 
Children aged 2 mo-6 y with 
infectious diarrhea (n=87) 
RDBPC Mixture of 3  
L. rhamnosus(1.2x 
10
10 
cfu)(573L/1; 
573L/2; 573L/3) or 
placebo 2x daily, for 
5d  
RV diarrhea duration ↓ Szymanski 
et al. 2006 
Children aged 6 mo-2 y with 
acute watery diarrhea 
(n=224) 
RDBPC, 24 
mo 
ORS with 
L.acidophilus, 
L. paracasei,  
L. bulgaricus,  
L. plantarum, B. breve, 
B. infantis, B. longum,  
S.thermophilus 
(VSL#3),9x10
10
/sachet 
or placebo mixed in  
breast milk, formula 
milk,ORS or water 
daily for 4d  
Recovery from acute RV 
diarrhea ↑ 
Frequency of ORS 
administration ↓ 
Stool volume losses 
during diarrhea ↓ 
Dubey et 
al.  2008 
Hospitalized children aged 
3mo - 3 y (n=80)  
RDBPC ORS+ placebo or ORS 
+ S. faecals T-110, 
Clostridium butyricum 
TO-A, Bacillus 
mesentericus TO-A, 
 L. sporogenes 
(Bifilac
TM
)  dissolved 
 in water 3x daily up 
to 14d. 
No. of episodes 
(frequency) of diarrhea in 
a day ↓ 
Mean duration of 
diarrhea (in days)↓ 
Degree of dehydration ↓ 
Duration and volume of 
ORS  and intravenous 
fluid therapy ↓ 
Duration of RV 
shedding ↓ 
Naraya-
nappa et 
al. 2008 
Children  with acute RV 
gastroenteritis (n=23) 
Open-label 
randomized 
trial 
Low (2x10
8
) or high 
dose (6x10
8
 cfu) of 
L. rhamnosus 35 or 
placebo for 3d 
In high-dose group: 
Fecal RV concentration ↓ 
Fang et al.  
2009 
Children aged 1-23 mo 
hospitalized for acute RV 
diarrhea (n=64)  
RDBPC, 8 mo ORS+ placebo or ORS+ 
Saccharomyces 
boulardii (10
10 
cfu) or 
ORS+ combination of 
L. acidophilus, 
L.rhamnosus,  
B. longum and 
 S. boulardii (10
7
-10
10
 
cfu) 2x daily for 5d 
Both supplementations: 
duration of diarrhea ↓ 
(significant only for  
single species product) 
S.boulardii:  duration of 
fever ↓ 
Grandy et 
al.  2010 
Infants aged 6-48 mo with 
acute diarrhea (n=186) 
RDBPC S.boulardii (4 x10
9
 
cells) or placebo orally 
2x daily  for 5d 
Diarrhea duration ↓ 
RV diarrhea ↓ 
RV in stool ↔ 
Corrêa et 
al. 2011 
RDBPC = randomized double-blind placebo-controlled; DBPC = double-blind placebo-controlled; RPC = 
randomized placebo-controlled; mo = months; y = years; ↑ = increase; ↓ = decrease; ↔ = no effect   
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3.4  THE EFFECTS OF NONVIABLE PROBIOTICS ON VIRUS INFECTIONS 
 
Increasing evidence shows that killed/nonviable/inactive bacteria, products derived from 
bacteria, or end products of bacterial growth could provide some health benefits (Kataria et 
al., 2009, Lahtinen and Endo, 2012). In addition, nonviable bacteria would serve as a great 
potential for food industry by providing new product applications, increasing product shelf 
life, and reducing storage costs. However, because they are not alive when administrated they 
cannot be considered as probiotics (Sanders et al., 2007, Sanders et al., 2010). Probiotics are 
inactivated with heat-inactivation in 70-120oC, sonication, UV- or γ-radiation, freezing, and 
acidification. Different inactivation methods may have an impact on the cell wall components 
of bacteria, which affect the adhesion properties of bacteria in the gut epithelium (Ouwehand 
et al., 2000). In addition, inactivation may release biological compounds from the cytosol of 
bacteria, leading possibly to dissimilar effects than effects induced by viable bacteria.  
 
The effects of nonviable bacteria in virus infections have been addressed in several studies. In 
children, live L. rhamnosus GG enhanced RV specific antibody response over inactivated 
product form (Kaila et al., 1995). In mice, L. rhamnosus GG was more effective than 
inactivated product form in protection against RV diarrhea (Pant et al., 2007).  In respiratory 
virus infections using mice models, orally or intranasally administered boiled or heat killed L. 
plantarum 06CC2 and L-137, L. gasseri, or L. pentosus strain b240 were effective against 
influenza virus infection (Hori et al., 2001, Maeda et al., 2009, Izumo et al., 2010, Izumo et 
al., 2011, Kobayashi et al., 2011, Takeda et al., 2011, Kawase et al., 2012). However, these 
studies did not include viable strains in comparison.  In mice, administration of live or heat-
inactivated lactobacilli equally protected against lethal infection with pneumonia virus 
(Gabryszewski et al., 2011). In addition, in pig alveolar macrophages live or heat-inactivated 
lactobacilli and bifdobacteria equally increased cell survival against vesicular stomatitis virus 
infection depending on strain used (Ivec et al., 2007). Another study, however, showed that 
live Lactobacillus strains conferred protection against influenza infection in mice more 
efficiently than nonviable strains (Youn et al., 2012).   
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The aim of this series of studies was to evaluate the effects of probiotic bacteria, especially 
Lactobacillus rhamnosus GG in viral respiratory and gastrointestinal infections in 
experimental models and in children. A special emphasis was on the questions, whether 
viability of a strain plays a role in beneficial effects of probiotics, and whether combination of 
strains is more effective over single strains.  
 
The specific aims were: 
 
1. To develop a novel colorimetric neutralization assay for detection of influenza virus 
antibodies from human sera for vaccine research (I). 
 
2. To compare the ability of combination of probiotic and potentially probiotic bacteria 
to induce immune responses over single strains in primary cell culture using human 
monocyte-derived macrophages (II). 
 
3. To characterize the effects of the viable and nonviable L. rhamnosus GG in rotavirus 
infection in neonatal rats (III). 
 
4.  To evaluate whether L. rhamnosus GG is effective in reducing common respiratory 
virus infections in children (IV). 
 
5. To investigate whether a combination of probiotics including L. rhamnosus GG 
reduces nasopharyngeal occurrence of human bocavirus in otitis-prone children (V).  
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1 STUDY MATERIAL AND SUBJECTS 
1.1 BACTERIAL STRAINS AND PRODUCTS (II-IV) 
 
Five potentially probiotic strains or known probiotic strains used in the experiments were 
obtained from Valio Ltd (Helsinki, Finland) (Table 9). In Study II, bacteria were stored in 
skimmed milk at -70oC and passaged three times before use in stimulation experiments as 
described previously (Miettinen et al., 1998, Kekkonen et al., 2008). For stimulation 
experiments, bacteria were cultured to a late logarithmic phase, and the number of bacteria 
was determined by counting in a Petroff -Hauser counting chamber. In Study III, viable L. 
rhamnosus GG (GG) stock (1011 cfu/ml) was aliquoted in MRS culture medium broth and 
stored at -20oC prior use. Powdered nonviable GG (the method of inactivation is a trade 
secret by Valio Ltd) in equivalent cfu number of 1011 cfu/g of viable GG was maintained at 
room temperature. Prior experiments, live GG was thawed and nonviable GG weighed, and 
both were prepared daily in PBS at a concentration of 3x109cfu/ml.  In Study IV, 
unsweetened Gefilus® milk containing 1 % fat included concentrations of GG ranging from 
105-106 cfu/ml depending on shelf life. In Study V, the gelatine capsules contained a mixture 
of four probiotic strains (GG, L. rhamnosus Lc705 (Lc705), B. breve 99 (Bb99), 
Propionibacterium freudenreichii JS (PJS)), 8-9 x 109 cfu/capsule of each strain. Bacterial 
strains used in this study are presented in more detail in Table 9. 
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Table 9. Bacteria used in the study. 
Bacterial 
strain 
Abbreviation 
in the study  
ATCC/ 
DSM 
number 
Culture 
medium 
Growth 
conditions 
Use in the 
experiments 
Study 
number 
 
Lactococcus lactis 
ssp.cremoris 
ARH74 
 
 
ARH74 
 
DSM 
18891 
 
MRS medium 
and M17 broth 
with 20g/ 
L-lactose (2%) 
 
22
o
C, aerobic 
 
In vitro 
 
II 
Lactobacillus 
rhamnosus GG 
GG ATCC 
53103 
de Man, Rogosa 
and Sharpe 
(MRS) medium 
37
o
C, aerobic In vitro, PBS 
supplement, 
milk, capsules 
II-V 
Lactobacillus 
rhamnosus Lc705 
 
Lc705 DSM 
7061 
MRS medium 37
o
C, aerobic In vitro,  
capsules 
II, V 
Bifidobacterium  
breve Bb99 
Bb99 DSM 
13692 
MRS medium 
with cysteine 
37
o
C, 
anaerobic 
Capsules V 
Propionibacterium 
freudenreichii JS 
PJS DSM 
7067 
Propionimedium 30
o
C, aerobic Capsules V 
1.2 VIRUS STRAINS AND CULTURES (I, III) 
 
In Study I, influenza A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and 
B/Finland/159/02 virus strains were obtained as egg isolates from the WHO Collaborating 
Center for Reference and Research on Influenza in London (UK) and adapted to grow in 
MDCK cells.   
 
In Study II, Influenza virus strain A/Beijing/353/89 (H3N2) egg isolate were obtained from 
the National Institute for Health and Welfare (Helsinki Finland) and grown as described 
previously (Ronni et al., 1995). 
 
In Study III, simian RV SA-11 strain was obtained from Department of Food Hygiene and 
Environmental Health (University of Helsinki, Finland).  RV was propagated in a continuous 
cell line of rhesus monkey kidney cells, MA-104. The cells were cultivated in minimal 
essential medium (MEM) containing 10% heat-inactivated fetal bovine serum supplemented 
with 2 mM L-glutamine, penicillin and streptomycin in roller flasks in a roller apparatus at 
37°C. When the cells had a confluency of 70-80%, they were inoculated from a stock 
containing 108 pfu/ml of plaque-purified RVs. Before inoculation the RV stock was treated 
with 10-20 μg/ml (final concentration) of trypsin (Sigma, St Louis, USA) for 30 min at 37oC. 
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RV stock at dilution of 10-4 was added to each roller bottle. After incubation for one hour (h), 
30 ml of serum-free MEM with 1μg/mL of trypsin was added, and the cultivation was 
continued for 48h at 37°C. RVs were harvested by freeze-thawing of cells three times, cell 
debris was removed by low-speed centrifugation, and the supernatant was collected, divided 
into aliquots, and stored at -70°C until use. The RV titer was determined as 1.4x108 pfu/ml. 
1.3 CELL CULTURES  
1.3.1 Madin-Darby canine-kidney cells (I) 
 
Madin-Darby canine kidney (MDCK) cells (CCL-34, ATCC, Manassas, VA, USA) were 
grown in Eagle’s MEM (EMEM) supplemented with non-essential amino acids (NEAA), 
penicillin (100 000 U/ml), streptomycin (78 000 U/ml) and 0.2% bovine serum  albumin 
(BSA), and maintained at 37oC in a 5% CO2 humidified atmosphere. The cells were 
subcultured at a split ratio of 1:3–1:5 twice a week. For the NT, a serum free medium 
(Optipro SFMTM, Gibco, Invitrogen; Carlsbad, CA, USA) supplemented with 2mml-glutamin, 
antibiotics, and 0.2% BSA was used. 
1.3.2 Differentation of macrophages from peripheral blood-derived monocytes (II)  
 
Human peripheral blood mononuclear cell (PBMC) - derived monocytes were purified by 
density gradient centrifugation over a Ficoll-Paque gradient (Amersham-Pharmacia Biotech, 
Uppsala Sweden) from freshly collected, leukocyte-rich buffy coats obtained from healthy 
blood donors (Finnish Red Cross Blood Transfusions Service, Helsinki, Finland) as described 
(Miettinen et al., 2000). Briefly, after washing the cells were resuspended in RPMI-1640 
supplemented with 2 mmol/L L-glutamine (Lonza Walkersville, Inc., Walkersville, MD, 
USA), 100 U/ml penicillin, 100 mg/ml streptomycin (Lonza), and 20 mmol/l HEPES 
(Lonza). For monocyte differentiation, PBMC were allowed to adhere to plastic six-wells 
(Falcon, Becton Dickinson, Franklin Lakes, NJ, USA) for one hour at +37oC in 5% CO2.  After 
incubation nonadherent cells were removed, and adherent cells were then grown for seven 
days in Macrophage SFM media (Gibco BRL, Paisley, Scotland), supplemented with 
antibiotics and recombinant GM-CSF at 10 ng/ml (Biosource, Camarillo, Ca, USA).  
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1.4 EXPERIMENTAL ANIMALS (III) 
 
Pregnant specific pathogen free Lewis rats were obtained from Harlan Laboratories Inc. 
(Horst, The Netherlands) and allowed to give birth naturally in the test facility. Prior to 
experiments, each litter was adjusted to six pups per dam. Litters were randomly assigned to 
four experimental groups (n=6 pups/group): rats infected with RV SA-11 alone (RV control 
group); nonviable GG treated + RV SA-11 infected rats (nonviable GG group); viable GG 
treated + RV SA-11 infected rats (viable GG group); and MEM control rats (healthy control 
group). Control and inoculated groups were housed in the same individually ventilated 
Scantainer (Scanburg, Denmark), and each RV infected group in their own Scantainer, in 
normal rat cage (Makrolon III) with Aspen chips bedding (Tapvei Oy, Kaavi, Finland) and 
nest material (Aspen chips PM90L/R). The temperature was 22±2ºC with relative humidity 
50-95 %. Lighting was artificial, 12h light and 12h dark (18:00-06:00). Food (TEKLAD 
T.2916 IRR*; Irradiated Global 16%, Rodent Diet for mice and rats, Harlan) and deionized 
water were autoclaved and provided ad libitum from the day of the rats’ arrival until the 
completion of the experiments.  
1.5 CHILDREN (IV-V)  
 
In Study IV, nasopharyngeal swab (NPS) samples were obtained from children (aged 2-6 
years) attending day care five days a week in Northern Finland (Kumpu et al., 2012). 
Children with milk allergy, lactose intolerance, congenital heart disease requiring regular 
medication, malignant diseases, cytostatic treatment, use of biological rheumatic medication, 
continuous microbial medication, regular use of oral corticosteroids, diabetes, or 
simultaneous participation in other clinical trials had been excluded from the study.  
 
In Study V, NPS samples were obtained from otitis-prone children (aged 10 months to 6 
years) (Hatakka et al., 2007). Children had been classified as otitis-prone if they had ≥4 AOM 
episodes during the preceding 12 months or ≥3 episodes during the preceding six months. 
Children on regular medication, with chronic illnesses, Down’s syndrome, lip or palatal cleft, 
or otitis media with effusion had been excluded. Those children who had undergone 
adenoidectomy or tympanostomy had been included if they had suffered the required 
number of AOM episodes.  
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2 STUDY DESIGNS  
2.1 IN VITRO EXPERIMENTS (I-II)  
2.1.1 Colorimetric neutralization test (I) 
 
A colorimetric cell proliferation assay was developed for the determination of neutralizing 
antibodies of 40 healthy adult individuals after immunization with seasonal, trivalent, 
inactivated influenza vaccine. Prior testing, method was optimized with a different set of 
variables (e.g. cell number, virus concentration, and different serum dilutions). In the final 
test protocol (Figure 5) a flat-bottom 96-well cell culture plates (Nunc, A.S.Roskilde, 
Denmark) were  first pre-treated with SFM containing 10% FBS (100 μl/well) for 3h at +37oC 
5% CO2. Second, test sera used in optimization were heat-inactivated for 30 min at +56oC. 
Dilutions of the influenza stock viruses and the test sera were prepared in SFM containing 4 
μg/ml of TPCK–trypsin (Sigma Chemical Co., St. Louis, MO, USA). Sera were serially diluted 
in half-logarithmic steps starting from a dilution of 1:16.5. Then, a 100 μl volume of each 
serum dilution or medium control was combined with an equal volume of medium 
containing approximately 40 pfu of influenza virus. Third, the serum-virus mixtures were 
incubated at +37oC for 90 min. Fourth, each serum–virus mixture was transferred to 
triplicate wells (50 μl/well), and 50 μl of a fresh suspension of MDCK cells was added (104 
cells/well). Wells containing serum dilutions 1:33–1:100 without viruses, virus dilutions in 
the absence of test sera, wells containing only MDCK cells in SFM, and wells containing plain 
SFM media were included on each assay plate as controls. The plates were centrifuged at 
170g for 20 min. Fifth, the plates were incubated at +37oC 5% CO2 for 72h, after which WST-
1-reagent (Roche diagnostics, Basel, Switzerland) (10 μ/well) was added. The plates were 
further incubated at 37oC for 4h allowing the color reaction development. Optical density was 
measured with an ELISA-spectrophotometer (Thermo Electron Corporation, Multiscan Ex; 
Vantaa, Finland) at 450 nm with 650 nm as a reference. To calculate neutralizing antibody 
titers, mean absorbance value from three parallel wells was calculated, after the mean value 
from the system-background control wells had been subtracted. Neutralizing activity (percent 
inhibition) was calculated for each serum dilution and the antibody titers were determined 
using the following equation: 
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 A450 of serum dilution − A450 of virus control × 100 
A450 of serum control − A450 of virus control 
 
 
The neutralizing antibody titer was expressed as the reciprocal of the highest serum 
dilution that inhibited virus growth by ≥50%. 
 
 
 
 
Figure 5. Schematic illustration of colorimetric NT protocol. 
2.1.2 Bacterial stimulation experiments (II) 
 
All experiments were performed with cells obtained from four blood donors. Stimulation 
experiments were performed in RPMI-1640 medium with supplements (Figure 6). 
Macrophages were stimulated with viable probiotic bacteria: host cell ratio of 1:1 for 24h at 
37°C in 5% CO2. When the cells were stimulated with a combination of GG and Lc705, equal 
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numbers of strains were used and the sum bacterial dose of the combinations was 1:1 of a 
bacteria: host cell ratio. Cell culture supernatants and cells from different donors were 
collected 24h after bacterial stimulation and pooled. In the influenza virus experiments, after 
probiotic stimulation, macrophages were challenged immediately with influenza virus (viral 
dilutions 1:1000 or 1:5000). After 1h of virus infection in +37°C in 5% CO2, the cells were 
washed with PBS and fresh RPMI-1640 medium containing 10% heat-inactivated fetal bovine 
serum (Integro Ltd., Zaandam, The Netherlands) was added. Cell culture supernatants and 
cells from different donors were collected 6h and 24h after virus infection and pooled.  All 
samples were stored at -20oC for cytokine and chemokine measurements.  
 
 
 
Figure 6. Schematic illustration of bacterial stimulation experiments-protocol. 
2.2 ANIMAL EXPERIMENTS (III)  
 
The summary of the study design is presented in Figure 7. Briefly, the pups were 
weighed at fixed times daily before and twice a day after RV infection.  At the age of two days, 
the pups received daily a single dose of 500 μl of either nonviable or viable GG 
supplementation (1.5x108 cfu/pup). RV (total amount of 108 pfu/pup) was inoculated in three 
separate doses at the age of five days (2x300 μl) and six days (1x120 μl). Similarly, MEM 
(100xglutamine, penicillin 100 IU/ml, streptomycin 100 μg/ml) was administered for healthy 
controls. The rat pups were randomized for exsanguination from either two or three days 
post infection at the age of seven and eight days. Blood samples were collected by 
decapitation into EDTA tubes (Venosafe™), and the plasma was obtained by centrifugation 
(10 min, 4000 rpm), and frozen at -20oC. After blood sampling, the GI tract was removed for 
macroscopic observations. The small intestine, colon, and feces were collected and weighed 
separately, and stored in -80°C. Feces were collected by carefully emptying the colon and 
rectum. The consistency of feces was classified from 0-3 using a four tier system: 0=normal 
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feces, 1=slight diarrhea (feces pale but solid), 2=moderate diarrhea (feces pale and semi-
solid), 3=strong diarrhea (feces clearly wet).  
 
 
 
Figure 7.   Schematic representation of study design of animal experiments. 
2.3 CLINICAL INTERVENTION EXPERIMENTS (IV-V)  
 
The characteristics of the Studies IV and V are presented in Table 10. Study IV was a 
substudy of a randomized, double-blind and placebo-controlled parallel group six months 
intervention study investigating whether GG can decrease respiratory illness in children 
attending day care centres in Kainuu and Oulu regions in Finland in October 2009 - April 
2010 (Kumpu et al., 2012). A total of 523 children aged 2 to 6 years, who fulfilled the 
previously reported inclusion criteria, were enrolled in to the study and randomized to 
receive either control milk (n= 262) or the same milk with GG (n=261) on three daily meals. 
During the intervention, whenever a subject experienced symptoms of respiratory or 
gastrointestinal infection that, according to parents’ judgement, required physician’s 
appointment, parents were advised to take the child to a study physician. In addition to 
clinical assessment and treatment, study physicians filled out a structured questionnaire 
regarding information on respiratory symptoms, and collected a NPS sample by a deep nasal 
swab using flocked-tip nylon swabs. Swabs were immediately submerged into a vial 
containing 3 ml of universal transport medium (UTM-RT, Copan, Diagnostics Inc., Murrieta, 
CA), and then stored at -70oC. For the present study, a total of 315 NPS samples were 
MATERIALS AND METHODS 
61 
 
available from 194 children (97 in the placebo and 97 in the probiotic group).  A total of 14 
respiratory viruses were analyzed from the NPS samples.   
 
Study V was conducted in conjunction with two other substudies (Blomgren et al., 2004, 
Pitkäranta et al., 2006) with a study population part of a larger project described by Hatakka 
and others (Hatakka et al., 2007). Briefly, in a double-blind, placebo-controlled, randomized, 
6-month intervention study in September 2000 - April 2001, originally 269 otitis-prone 
children (from 9 months to 5.6 years old) consumed daily either one capsule of probiotics 
(GG, Lc705, Bb99, and PJS) (n=135) or placebo (n=134). NPS samples were collected at the 
scheduled baseline visit in autumn, at the first follow-up visit after three months in winter, 
and at the final visit after six months in spring. NPS samples were collected from the 
nasopharynx with a calcium alginate swab through the nostril. The swab was immediately 
immersed in a tube containing 1 ml of STGG transport medium The STGG tube with the swab 
was vortexed immediately, stored in the refrigerator for maximum 8h, and then frozen at -70 
oC before analysis.  Parents had received advice to avoid days when the child had respiratory 
symptoms when making scheduled collection visits. Parents had to keep daily diaries, 
including signs and symptoms of AOM and respiratory infections, such as fever, earache, 
otorrhoea, rhinitis, cough, sore throat, chest wheezes, or night restlessness, and listing visits 
to health care authorities, and of the use of any medication. For the present study, all three 
NPS samples were available from 152 otitis-prone children (105 in the placebo and 47 in the 
probiotic group). Of these, the presence and persistence of HBoV1-4 were analyzed. 
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Table 10. Study characteristics of the clinical intervention experiments. 
Characteristics 
Study IV 
     Children  
Study V 
Otitis-prone children  
Probiotic Placebo Probiotic Placebo 
No.of children included in the analysis 97 97 47 105 
No.of collected NPS samples 160 155 141 315 
Monthly distribution of  collected NPS  
      September 0 0 
47 105 
  October 11 24 
  November 35 30 
    December 23 16 
47 105 
  January 16 18 
  February 34 32 
    March 26 19 
47 105 
  April 15 16 
 
Viruses analyzed 
 
HRV, HEV, HBoV1-4, ADV, 
RSV,  influenza A/(H3N2),  
A(H1N1)pdm09,  influenza B, 
PIV1-3 
 
HBoV1-4 
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3 VIROLOGICAL, IMMUNOLOGICAL, AND SEROLOGICAL ANALYSIS (I-V)  
3.1 SEROLOGICAL TESTING (I) 
 
For comparing the sensitivity and sensitivity of NT with HI test to measure influenza 
virus  antibodies in serum, 40 pre- and post-vaccination serum pairs collected from army 
conscripts were tested. These conscripts had been immunized with the seasonal trivalent, 
inactivated influenza vaccine in autumn 2002, containing the three WHO recommended 
vaccine viruses A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Hong 
Kong/330/2001. Prevaccination sera (S1) were collected at the time of vaccination, and post-
vaccination sera (S2) were drawn approximately one month later. The serum samples were 
kept frozen at -70oC until testing, and were heat inactivated at +56oC for 30 min prior use. 
The HI test was performed according to standard procedures (Kendal et al., 1982) with 0.4% 
suspension of goose red blood cells and two hemagglutinating units of influenza virus 
antigens. Sera were tested in serial fourfold dilutions starting from 1:10. Next, S1 and S2 sera 
were analyzed with the newly developed NT as described in the section “Study designs”. A 
threefold or higher titer increase between the pre- and post-vaccination sera was considered 
significant for NT, a fourfold increase for HI test.  
3.2 IMMUNOLOGICAL MEASUREMENTS (II)  
 
Cytokine levels from the cell culture supernatants were analyzed by using ELISA. TNF-α 
were determined with antibody pairs and standards obtained from BD Pharmingen (San 
Diego, CA, U/SA) essentially as described (Miettinen et al., 1998). IL-1β was determined with 
antibody pairs and standards obtained from R&D Systems (R&D Systems, Inc, Minneapolis, 
MI, USA). The bead based analyte detection assay for quantitative detection of IL-6, IL-10, 
IL-12 p70, CCL2/monocyte chemoattractant protein-1 (MCP-1) and CXCL10/IFN-inducible 
protein 10 (IP-10) were performed with FlowCytomix Human Simplex Kits (Bender 
MedSystems GmbH, Vienna, Austria) in capillary tubes following the manufacturer’s 
protocol. Flow cytomix assay were run with BD FACSCalibur™ flow cytometer (BD 
Biosciences, San Jose, CA, USA.)  
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3.3 VIROLOGICAL DIAGNOSTICS (III-V) 
 
The summary of viral detection methods used in the studies III-V is presented in Table 
11. In Study III, prior nucleic acid extraction, frozen small intestine, colon, and feces were 
processed as follows: Colon and the entire small intestine with its contents were 
homogenized with sterile glass rods, and 30 mg of homogenized tissue was added into 600 μl 
of RLT buffer (Qiagen) and incubated for +37oC 10 min in water bath.  Prior RNA extraction, 
the lysate was centrifugated in a QIAshredder (Qiagen) (2 min, 12 000 rpm).  Feces were 
processed on ice in 200 μl of 10% protease-inhibitor solution containing 1% BSA, 10 mM 
pefabloc (Roche Applied Science, Mannheim, Germany), 100 μg/ml aprotinin (Sigma-
Aldrich, St. Louis, MO, USA) 100 μg/ml leupeptin (Sigma-Aldrich) in EMEM I (Gibco, 
Carlsbad, CA) supplemented with 5% FCS and 20 mM Hepes (pH 7.4). Suspensions were 
vortexed with sterile glass beads, centrifugated (10 min, 5000 rpm), and viral RNA was 
extracted from supernatants. 
 
Table 11. The summary of viral detection methods. 
Virus Sample Nucleic acid extraction  PCR Study 
 
Rotavirus 
SA-11 
 
Plasma 
 
BioSprint® 96 One For All 
Vet-kit (Qiagen) 
 
High-Capasity cDNA Reverse 
Transcription Kit  
(Applied Biosystems), 
 real time qPCR, modified 
 (Li et al., 2010) 
 
III 
Small intestine RNeasy Mini Kit (Qiagen), 
BioSprint® 96 One For All 
Vet-kit (Qiagen)  
Colon 
Feces E.Z.N.A.® Total RNA Kit 
(Omega Bio-Tek) 
Rhinovirus NPS BioSprint® 96 One For All 
Vet-kit 
Real-time PCR assays 
(Taqman Chemistry), multiplex 
 RT PCR-hybridization assays 
(Blomqvist et al., 1999) 
IV, V 
Enterovirus NPS IV, V 
Bocavirus 1-4 NPS BioSprint® 96 One For All 
Vet-kit, QIAamp DNA Mini 
Kit (Qiagen)  
HBoV1 real time qPCR 
(Allander et al., 2007),  
multiplex real time qPCR  
(Kantola et al., 2010) 
IV, V 
Influenza A 
and B virus 
 
NPS BioSprint® 96 One For All 
Vet-kit  
cDNA RT, real-time multiplex PCR 
(Templeton et al., 2004, Rönkkö et 
al., 2011, Akinloye et al., 2011) 
IV 
Respiratory 
syncytial virus 
 
NPS IV 
Parainfluenza 
virus 1-3 
 
NPS IV 
Adenovirus NPS Real-time PCR Quantitect  
SYBR Green PCR  (Qiagen) 
(Akinloye et al.,2011)   
IV 
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4 STATISTICAL ANALYSES 
 
The statistical analyses in studies I-V were performed using SPSS software versions 15.0-
18.0 (SPSS Inc, Chicago, IL, USA). In all studies, P-values <0.05 were considered statistically 
significant. 
 
In Study I, during optimization of NT, the intra-assay and inter-assay variations of the test 
results were determined, and the result was given as a coefficient of variation (CV). When 
comparing the HI and NT test results, HI and NT titers were converted into logarithmic 
values, and the comparisons between the tests were executed with Student’s two-sided t-test. 
HI and NT titers below the lower limit of detection of the assay were given a value of 5. 
Antibody titer increases between HI and NT were compared by using the X2-test. Also the 
correlation coefficients between the HI and NT test results were calculated.  
 
In Study II, data were analyzed by a one-way analysis of variance (ANOVA), followed by 
Bonferroni’s post hoc test. 
 
In Study III, ANOVA was applied to compare the groups with respect to weight gain and 
tissue swelling, and the results are given as means with SEM. In cases of significant global p-
values, multiple comparisons were performed and the p-values were Bonferroni corrected. 
RV diarrhea occurrence and severity between the study groups were analyzed using logistic 
regression analysis. Statistical differences in the CT-values between SA-11 RV infected groups 
were analyzed using the Kruskal-Wallis test (global test) and Mann-Whitney U-test (pair-
wise comparisons).  
 
In Study IV, the results are presented as counts with percentages, means with 95 % 
confidence intervals (95% CI). Number of symptom days per month (incidence rates) and P-
value between groups concerning this endpoint was calculated by Poisson regression model. 
The differences between study groups in viral findings were tested by permutation type 
probit regressions for which the standard error was adjusted for 194 clusters (number of 
children). For HBoV virus, only HBoV positive samples with high viral load (>10 000 
copies/ml) were included in the analyses. The 95%CI for the number of symptoms were 
obtained by bias-corrected bootstrapping (2000 replications).  
 
In Study V, HBoV was assessed as positive or negative by four positivity criteria (>100, 
>1000, >10 000 and >100 000 copies/ml of sample). The association between HBoV DNA-
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positivity and respiratory symptoms from 2-week (sampling day ± 1 week) and 4-week 
(sampling day ± 2 weeks) time-periods was analyzed with logistic regression analysis, and 
GEE (generalized estimating equations) using information on respiratory symptoms 
provided by parents. The presence of respiratory symptoms in HBoV DNA-positive children 
were compared to those of HBoV DNA-negative children, with results as odds ratios (OR) 
with 95% confidence intervals. Logistic regression analysis allowed study of any possible 
effect of probiotic intervention on HBoV. Results are unadjusted (crude) and baseline-
adjusted odds ratios (OR) with 95% confidence intervals. GEE analysis allowed inclusion of 
3- and 6- month visits simultaneously and baseline positivity was a categorical covariate. 
 
5 ETHICS 
 
In Study II, the ethical permission to use the freshly collected, leukocyte-rich buffy coats 
obtained from healthy blood donors (Finnish Red Cross Transfusion Service, Helsinki, 
Finland) was given by the ethics committee of the Finnish Red Cross Transfusion Service in 
Helsinki. Study III was approved by the Animal Care and Use Committee of the State 
Provincial Office of Southern Finland (license number ESAVI-2010-06221_Ym-23). In 
Studies IV and V, the study protocol was approved by the ethics committee of Joint Authority 
of Kainuu Region (IV) (registered to http://clinicaltrials.gov with identifier NCT01014676), 
and by the ethics committee of Helsinki University Central Hospital (V). Before entering to 
the studies IV and V, the guardians of the children gave their written informed consent. 
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1 DEVELOPMENT AND EVALUATION OF COLORIMETRIC 
NEUTRALIZATION TEST (I) 
 
In Study I, a novel colorimetric neutralization test (NT) for the measurement of influenza-
specific antibodies in human sera was developed. The assay is based on the colorimetric 
measurement of formazan salt of metabolic active cells. After parameter optimization, NT 
test showed high reproducibility evidenced by low intra- and inter-assay variation. In 
addition, the pattern of significant antibody rises was similar between parallel assays. As a 
proof of concept, 40 influenza pre- and post-vaccination serum pairs were tested by the 
newly developed NT, and the results were compared with those obtained by the standard HI 
test. Overall, there was a good correlation against influenza A/New Caledonia/20/99, 
A/Panama/2007/99, and B/Fin/159/0 vaccine viruses between the HI and NT pre- and post 
vaccination antibody titers.  Moreover, the neutralizing antibody titers (GMT) to all vaccine 
viruses were significantly higher than the corresponding HI titers (P<0.0001) (Figure 8). In 
addition, NT revealed low pre-vaccination titers in some sera that remained negative by the 
HI test. Almost all of the 40 serum pairs exhibited significant titer increases to the H1N1 and 
the influenza B viruses as determined by both test principles (Table 12). More significant 
antibody increases, particularly against the H3N2 viruses, were detected by the NT, 
suggesting a higher sensitivity of the assay for detection of influenza virus antibodies.  
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Figure 8. Geometric mean titers (GMT with 95% CI) from pre- (S1) and post-vaccination 
serum pairs (S2) obtained with HI and NT in 40 subjects immunized with trivalent seasonal 
influenza vaccine. GMT from all viruses HI vs. NT: P<0.0001 (unpaired t-test). 
 
 
Table 12. Distribution between pre- and post-vaccination antibody titer increases obtained 
with HI and NT in 40 subjects immunized with trivalent seasonal influenza vaccine.  
Titer increase 
(fold change) 
No. of samples (%) 
A/New Caledonia/20/99  
 
A/Panama/2007/99 
 
B/Finland/159/02 
HI NT   HI NT   HI NT 
<3-4 3 (8) 1 (3) 
 
14 (35)
a
 3 (8) 
 
3 (8) 1 (3) 
3-4 5 (13) 8 (20) 
 
7 (18) 15 (38)
b
 
 
7 (18) 14 (35) 
≥8-20 19 (48) 16 (40) 
 
12 (30) 14 (35) 
 
19 (48) 13 (33) 
≥30-64 7 (18) 10 (25) 
 
7 (18) 6 (15) 
 
10 (25) 7 (18) 
≥100 6 (15) 5 (13)   0 (0) 2 (5)   1 (3) 5 (13) 
Total no.of 
significant 
antibody 
rises (%)
c
 37 (93) 39 (98)   26 (65) 37 (93)
d
   37 (93) 39 (98) 
a
 HI vs. NT: P= 0.003 
b
 HI vs. NT: P= 0.045 
c
 Significant antibody rise for HI ≥4, and for NT ≥3, respectively 
d
 HI vs. NT: P= 0.003
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2 IN VITRO SCREENING OF IMMUNOMODULATORY EFFECTS OF 
PROBIOTICS ON HUMAN MACROPHAGES (II) 
 
The summary of bacteria-induced macrophage cytokine and chemokine responses is 
shown in Table 13. Overall, the combination of GG/Lc705 induced similar or weaker 
immunomodulatory responses than individual GG or Lc705. However, the combination of 
GG/Lc705 was effective in enhancing IL-1β response over Lc705 by 1.5 fold, suggesting that 
the combination has some synergistic potential over individual strain. In addition, the 
combination induced TNF-α, IL-1β, IL-6, and IL-10 production more strongly than ARH74. 
However, ARH74 was the most potent inducer of chemokines MCP-1 and IP-10. The 
potential of these bacteria to enhance proinflammatory (TNF-α and IL-β) cytokine 
production in response to influenza A virus infection was analyzed as well (unpublished 
results). After 6h of influenza virus infection, GG and Lc705 individually enhanced 
macrophage TNF-α and IL-β production by 1.3-3.0 fold against viral challenge. The 
combination of GG/Lc705 or ARH74 had no enhanced effect. However, the study virus alone 
with used concentrations failed to induce any cytokine production in control cells, and thus 
did not allow evaluation of probiotic’s effects during influenza infection. 
 
Table 13. Cytokine and chemokine production profiles of monocyte-derived macrophages 
after 24h of bacterial stimulation. The number of + -symbols indicates the order of 
magnitude of response when comparing the immunomodulatory effects between bacterial 
strains. 0 indicates no effect. 
Cytokine or chemokine response 
Bacterial strain 
GG Lc705 GG/Lc705 ARH74 
TNF-α +++ ++ ++ + 
IL-6 +++ +++ ++ + 
IL-1β +++ + ++ 0 
IL-10 ++ ++ + 0 
IL-12 0 + 0 0 
MCP-1 ++ ++ + +++ 
IP-10 + ++ + +++ 
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3 THE EFFECTS OF  NONVIABLE PROBIOTIC IN ROTAVIRUS INFECTION 
IN RATS (III) 
3.1 CLINICAL INDICES AFTER ROTAVIRUS INFECTION 
 
The summary of clinical indices of rats following RV infection is presented in Table 14.  
After RV inoculations on days 5 and 6, total body weight increased slightly more effectively in 
the viable GG group than in the nonviable GG group.  On day 7 (after 2 days of RV infection), 
the viable and nonviable GG group gained significantly more weight than the RV group 
without probiotics (36% (P=0.001) and 28% (P=0.031), respectively). In addition, when 
compared with the RV control group, both viable and nonviable GG reduced the weight ratio 
of the colon/animal to the same level as in the healthy control group, with reductions of 22% 
(P=0.002) and 28% (P<0.001), respectively. Concerning diarrhea incidence, diarrhea 
increased moderately in both GG groups. However, neither the incidence nor severity of 
diarrhea in the GG groups was statistically significant (P>0.05) as compared with the RV 
control group. Moreover, observed diarrhea did not provoke weight loss or death. 
 
Table 14. Clinical indices of the study groups of the neonatal rats after RV infection.  
Clinical indices 
Viable  
GG 
Nonviable 
 GG 
RV 
 control 
Healthy  
control  
P-value 
Weight gain (%)
a
 102.9 (12.4) 92.0 (7.7) 95.2 (9.8) 116.7 (13.8) ns 
Colon weight
b
 2.8 (0.1) 2.5 (0.08) 3.5 (0.18) 2.6 (0.12) P<0.05
c
 
Diarrhea score  
(range)
d 
2.5 (1-3) 2.0 (1-3) 1.0 (0-2) 0.0 (0) ns 
a 
Total percentual weight gain of the rats after RV inoculations on days 5-6, mean ± SEM 
b
 Weight ratio of colon/animal mg/g, mean ± SEM 
c
 Viable GG vs. RV control, nonviable GG vs. RV control 
d
 Median with diarrhea score range 
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3.2 ROTAVIRUS POSITIVITY IN RAT TISSUES 
RV positivity was determined from plasma, small intestine, colon, and feces with RT-
qPCR. The number of RV PCR-positive samples in the study groups and their respective CT-
values are shown in Table 15. Overall, the RV control group had the largest number of RV 
PCR-positive samples among the RV infected groups, and the viable GG group the smallest. 
By comparing the CT- values between the groups, rats receiving viable GG had significantly 
less RV in the colon (P=0.027) when compared with the RV control group. Viable GG was 
also more effective than nonviable GG in reducing the quantity of RV in plasma (P=0.047). 
 
Table 15. RV detection from the tissues of neonatal rats.  
Tissue 
sample 
Viable GG 
 group 
Nonviable GG 
 group 
RV control  
group 
Healthy control 
group  
No.of 
positive 
samples
a
 
CT  
(range)
b 
No.of 
positive 
samples 
CT  
(range) 
No.of 
positive 
samples 
CT 
 (range) 
No.of 
positive 
samples 
CT 
(range) 
Plasma 6/6 33 (32-37) 6/6 31 (29-33) 6/6 32 (32-35) 0/5 >45 
Small 
intestine 2/6 44 (37- >45) 4/6 43 (37- >45) 5/6 41 (37- >45) 0/5 >45 
Colon 6/6 27 (27-28)
c
 6/6 25 (23-27) 6/6 25 (23-26) 0/5 >45 
Feces 3/6 42 (37- >45)
d
 4/6 41 (35- >45) 5/6 39 (35- >45) 0/5 >45 
a  
Samples with CT-values <45 was regarded as RV PCR positive 
b 
Mean number of CT values of all tested samples. Samples with CT-value >45 received a random value 
between 46-50 
c 
Viable GG vs. RV control: P=0.027 (Kruskall-Wallis test) 
d 
Viable GG vs. nonviable GG: P=0.047 (Kruskall-Wallis test) 
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4 THE EFFECTS OF PROBIOTICS ON RESPIRATORY VIRUSES IN 
CHILDREN (IV-V) 
4.1 THE NASOPHARYNGEAL OCCURRENCE OF VIRUSES  
 
In Study IV, the most commonly identified virus from 194 children was HRV (37.1%), 
followed by RSV (20.1%), PIV1 (19.6%), HEV (14.4%), influenza A(H1N1)pdm09 (12.9%), 
HBoV1 (6.2%), PIV2 (5.2%), ADV (4.6%), and influenza A(H3N2 ) (1.0%).  HBoV1 occurred 
at high load of 2.1% of children. In study V, of 152 otitis-prone children, 43 (28.3%) were 
HBoV1 DNA positive.  Of these, 26 (17.1%) exhibited a high load (>10 000 copies/ml of 
sample) of HBoV1 DNA. In addition, 16 (10.5%) of 152 children showed prolonged presence 
of HBoV1 DNA for at least three months, and one child for six months. In addition, two 
(1.3%) children had one negative sample between the two HBoV DNA-positive samples. 
Influenza B virus, PIV3, and HBoV2-4 were undetectable either from children in Study IV or 
HBoV2-4 from otitis-prone children in Study V. 
 
The monthly occurrence of all virus positive NPS samples is presented in Table 16  (Study 
IV) and in Figure 9 (Study V). In Study IV, RSV was most commonly detected in spring 
(February to March), whereas influenza A(H1N1)pdm09 was found more frequently in 
autumn (October to November). HRV was found in relatively high numbers throughout the 
28-week intervention. Of the more rarely encountered viruses, PIV2 was mainly detected 
from January to March, HBoV1 from November to April, ADV in November and December, 
and again between March and April. In study V, HBoV DNA was detected at all three study 
visits, with the highest occurrence at three months. At the initial study visit, 3.3% of the 
children carried a high load of HBoV DNA. After three months, the HBoV DNA prevalence 
among the NPS samples increased to 10.5%, but after three months, decreased to 7.9%.  
 
In Study IV, the majority of RSV and PIV2 were identified from children ≥4 years old. HEV 
predominated in the children under ≤3 years. HRV, ADV, influenza A virus subtypes, and 
PIV1 in Study IV, and HBoV1 in both studies were distributed almost equally between the age 
groups (unpublished results).  
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Table 16. The monthly occurrence (%) of respiratory viruses in the NPS samples of children 
(Study IV). 
Virus October November December January  February March April Total 
Rhinovirus 15 25 18 7 7 6 12 90 
Enterovirus 8 8 6 0 3 1 2 28 
Influenza 
A(H1N1)pdm09 7 16 0 1 1 0 0 25 
Influenza A(H3N2) 0 1 0 0 1 0 0 2 
Respiratory 
syncytial virus 0 0 1 2 18 17 1 39 
Parainfluenza virus 1 3 0 2 6 12 8 7 38 
Parainfluenza virus 2 0 0 0 0 4 5 1 10 
Adenovirus 0 2 1 0 0 2 4 9 
Bocavirus 1 0 2 2 3 1 2 2 12 
 
 
 
 
Figure 9. The monthly distribution (%) of HBoV1 viral loads in the NPS samples of otitis-
prone children (Study V). The number of virus positive samples was compared with the total 
number of samples collected in each scheduled collection times.  
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4.2 THE EFFECT OF PROBIOTIC INTERVENTION ON VIROLOGICAL FINDINGS 
 
Distribution of respiratory viruses between the study groups in Study IV and V is 
presented in Figure 10. In Study IV, the number of HRV, RSV, influenza A(H3N2), PIV2 
and HBoV1- positive samples distributed almost equally between the study groups. In the GG 
group, there was a nonsignificant lower risk for HEV (P=0.083), influenza A(H1N1)pdm09 
(P=0.12), and for ADV (P=0.095), but a seemingly opposite effect for PIV1 infections 
(P=0.035) 
 
In Study V, probiotic supplementation reduced significantly the number of HBoV1 DNA-
positive samples (>10 000 copies/ml) during the intervention period (probiotic vs. placebo: 
6.4% vs. 19.0%, baseline adjusted OR=0.25, 95% CI 0.07–0.94, P=0.039). A similar, though 
not statistically significant, reduction occurred when the results were analyzed by GEE 
(baseline adjusted OR=0.45, 95% CI=0.12–1.66, P=0.228), or when applying another HBoV1 
positivity criterion. In addition, to allow time for the intervention to take place, we included 
only the baseline HBoV1-negative children and analyzed the HBoV-positive children (by first 
occurrence of HBoV1), and found less HBoV1 in the probiotic group (probiotic vs. placebo: 
6.7% vs. 17.6%, OR=0.33, 95% CI=0.09–1.20, P=0.092). Probiotic intervention did not, 
however, reduce the occurrence of prolonged presence of HBoV over three months (probiotic 
vs. placebo:  8.5% vs. 11.4%, OR=0.72, 95% CI =0.22–2.360, P=0.589).  
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Figure 10. Distribution of respiratory viruses between the study groups in 315 NPS samples 
of children (Study IV), and distribution of HBoV1 positives in 465 NPS samples of otitis-prone 
children during intervention (Study V). Only results with HBoV positivity criterion >10 000 
copies/ml is shown.  
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In Study IV, the virus positive samples distributed similarly in the age groups between the 
study groups (results not shown).  In study V, there were more HBoV positive children in the 
placebo group than in the probiotic group in all age groups (0-2, 2-3, 3-5). However, the 
differences in HBoV positivities between groups were not statistically significant (Table 17).  
 
 
Table 17. The distribution (%) of HBoV positive children between the age groups in study 
groups in Study V. 
HBoV 
positivity 
(copies/ml) 
Age (years) 
0-2 2-3 3-5 
Placebo 
(n=51) 
Probiotic 
(n=24) 
Placebo 
(n=37) 
Probiotic 
(n=13) 
Placebo 
(n=17) 
Probiotic 
(n=10) 
>1000 18 (35) 7 (29) 9 (24) 3 (23) 5 (29) 1 (10) 
>10 000 12 (24) 4 (17) 6 (16) 0 3 (18) 1 (10) 
>100 000 6 (11) 1 (4) 3 (8) 0 1 (6) 1 (10) 
 
4.3 THE EFFECT OF PROBIOTIC INTERVENTION ON RESPIRATORY SYMPTOMS 
ASSOCIATED WITH VIROLOGICAL FINDINGS 
 
In Study IV, during the 28-week intervention period, the children in the GG group had 
less days with respiratory symptoms per month than the children in the placebo group (6.48 
[95 % CI 6.28 to 6.68] vs. 7.19 [95 % CI 6.98 to 7.41], P<0.001). However, probiotic 
intervention did not have an effect on the mean number of respiratory symptoms observed at 
the time of the positive viral sample collection. 
 
In Study V, during the 6-month follow-up, there were no statistically significant differences 
in children’s respiratory symptoms between the study groups of this substudy (median (IQR) 
number of days with respiratory symptoms: probiotic vs. placebo; 43 (30-64) vs. 47 (33-70), 
P>0.05). Overall, no association appeared between HBoV DNA-positive samples (>10 000 
copies/ml) and respiratory symptoms, either one or two weeks before and after each sample 
collection. As HBoV PCR-positivity in the nasopharynx alone is not a reliable marker of acute 
infection, interactions of HBoV positivity and probiotic treatment on the occurrence of 
respiratory symptoms were not analyzed. 
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This series of studies investigated the effects of probiotics especially L. rhamnosus GG on 
respiratory and gastrointestinal virus infections in experimental models and in children. A 
particular focus was on questions, whether viability of a probiotic is an important factor in 
probiotic-virus interaction, and whether a combination of probiotics is more effective than 
single strains.   
 
 
1 METHODOLOGICAL ASPECTS 
1.1 HUMAN MACROPHAGE PRIMARY CELL CULTURE MODEL 
 
Human monocyte derived macrophage model was applied for screening of 
immunomodulatory effects of probiotic combination and individual strains. Cytokine (TNF-
α, IL-1β, IL-6, IL-10, and IL-12) and chemokine (MCP-1, IP-10) responses were analyzed. 
Macrophages have an important role in innate immune response, as they upon activation 
produce a large variety of cytokines and chemokines. In addition, macrophages are essential 
in the pulmonary immune defense against respiratory viruses (Kohlmeier and Woodland, 
2009). The interaction with probiotic bacteria and the host takes place most likely on the gut 
epithelial cells, where probiotics may be ingested by macrophages (Sun et al., 2007), and 
further initiate innate and adaptive immune responses. In vitro cell culture models allow 
analysis of immunomodulatory effects of probiotics under highly controlled experimental 
conditions. Lactobacilli and bididobacteria are known to induce many immunomodulatory 
effects in human PBMC cells (Miettinen et al., 1998, Drouault-Holowacz et al., 2006, 
Gackowska et al., 2006, Helwig et al., 2006, Castellazzi et al., 2007, Foligne et al., 2007, 
Medina et al., 2007, Kekkonen et al., 2008, Dong et al., 2010, Van Hemert et al., 2010). 
 
 
 
 
DISCUSSION  
DISCUSSION 
78 
 
However, only few studies have characterized probiotic induced immune responses in human 
macrophages (Miettinen et al., 2000, Veckman et al., 2003, Miettinen et al., 2008, Latvala et 
al., 2011). In addition, this model would allow interaction studies between probiotics and 
influenza viruses (Pirhonen et al., 1999, Matikainen et al., 2000, Miettinen et al., 2000).  
 
Optimization of the cell culture conditions is a significant factor, which affects the reliability 
of the results. For example, the variation between blood donors should be minimized by 
using at least four donors on each experiment.  Of note, health status of the blood donors is 
controlled for potential infections with a health questionnaire of Finnish Red Cross 
Transfusion Service. In addition, the optimal bacteria: host cell ratio is critical. In 
monocyte/macrophage cultures, the bacteria: host ratio 1:1 is widely used, as it induces 
submaximal cytokine gene expression (Miettinen et al., 1998, Miettinen et al., 2000, 
Veckman et al., 2003). Moreover, the stimulation period of probiotics is an important factor 
for the magnitude of immune response. In the present study macrophages were stimulated 
with bacteria for 24h according to other studies for obtaining maximal immunomodulatory 
effect (Veckman et al., 2003, Miettinen et al., 2008). However, it is possible that synergistic 
effects of bacterial combination are more pronounced when stimulation is extended over 24h.  
 
Considering virus-bacteria-interaction studies, influenza virus alone failed to induce TNF-α 
or IL-1β production in our experiments possibly due to insufficient virus concentration. 
There is, however, evidence that influenza A virus is capable of inducing inflammatory 
response in this cell culture (Pirhonen et al., 1999). In order to obtain measurable effect, the 
virus dose must be increased. However, increased infection due to larger virus dose may 
weaken the cells and interfere with probiotic-host cell interaction, and lead further to false 
results.   
1.2 ROTAVIRUS INFECTION MODEL IN NEONATAL RATS 
 
In Study III, we examined whether a viability of a bacterial strain is an important factor in 
exerting the beneficial health effects of probiotics in virus infections.  Probiotics affect most 
likely through the gut mucosal system, where also the possible interactions with 
gastrointestinal viruses occur.  As the strongest evidence of health effects of L. rhamnosus 
GG (GG) in virus infections is the reduction of duration and severity of rotavirus (RV) 
induced diarrhea, we chose widely investigated RV rat model for probiotic viability 
evaluation and virus-host interactions studies.  These interactions have been investigated 
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only in few studies in animals (Duffy et al., 1994, Guérin-Danan et al., 2001, Pant et al., 
2007), and no reports exist on the effects of viability of GG in RV infection in a rat model. 
Heterologous simian RV SA-11 infection model in Lewis rats is considered highly valid for 
group A RV studies as these virus types replicate most efficiently in rats. Moreover, the size of 
the GI tract of neonatal rats allows pathophysiological studies (Guérin-Danan et al., 1998, 
Ciarlet et al., 2002). In the present study, RV SA-11 was effective in inducing diarrhea 2-3 
days of post-infection to the rat pups, which is in accordance with other studies (Guérin-
Danan et al., 2001, Pérez-Cano et al., 2007). Moreover, although RV diarrhea may last up to 
12 days, the onset of disease of the animals inoculated with RV SA11 occurs at three days of 
post-infection (Ciarlet et al., 2002).  The experimental protocol lacked GG control without 
RV, and thus we cannot confirm whether increased diarrhea observed in both GG groups 
were partly due to relatively large dose of GG (1.5x108 cfu/pup) with respect to the animal 
size. However, other rat and mice studies have observed decrease in diarrhea with equivalent 
bacterial concentrations (Guérin-Danan et al., 2001, Pant et al., 2007). In the present study, 
the rats were clinically healthy and their weight gain increased similarly as in the healthy 
control group. In contrast, in another study L.casei DN-114 001 failed to induce weight gain 
(Guérin-Danan et al., 2001), highlighting strain specific effects of probiotics in virus 
infections. Determination of histological differences would be valuable for examining this 
aspect further.  
1.3 VIROLOGICAL DETECTION METHODS 
 
In studies III, IV and V, viral occurrence was determined from different sample matrices 
with validated sensitive and specific PCR-methods, where positive and negative controls were 
included in each assay.  In RV studies RV antigens are often analyzed in fecal samples with 
ELISA (Guérin-Danan et al., 1998, Guérin-Danan et al., 2001, Ciarlet et al., 2002, Pérez-Cano 
et al., 2007).  However, in Study III the quantity of fecal samples was insufficient for reliable 
ELISA RV antigen analysis. Thus, RV quantity in the rat tissues was detected with modified 
semi-quantitative RT-PCR (Li et al., 2010). In addition, quantitative detection of RV allowed 
detection of virus positive samples even at low levels, which could have been otherwise 
missed.  In respiratory virus diagnostics, the addition of multiplex PCR enabled detection of 
multiple viruses from one sample. 
 
Drawbacks of PCR methods include factors such as specimen collection, transport, and the 
influence of nucleic acid extraction on the ability of amplification techniques to detect viral 
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nucleic acid. In Studies IV-V, no human bocavirus (HBoV) types 2-4 DNA was detectable 
from NPS samples. However, HBoV2 rarely occurs in respiratory secretions (Arthur et al., 
2009, Chieochansin et al., 2009, Kapoor et al., 2009, Kantola et al., 2010), and HBoV3 and 
HBoV4 have been identified only in stool samples (Arthur et al., 2009, Kantola et al., 2010, 
Kapoor et al., 2010). In Study IV, the overall positivity rate of the detected viruses was 
surprisingly low, as compared with other respiratory virus epidemiology studies conducted in 
Finland (Nokso-Koivisto et al., 2006, Ruohola et al., 2009). However, NPS samples in our 
study were collected in widely used transport media (UTM-RT), which is acknowledged for 
long stability and preservation of viability for viral nucleic acid containing samples (Walsh et 
al., 2008, Luinstra et al., 2011). In addition, the analytic processes were executed with 
validated nucleic acid and PCR procedures. Some viral infections were probably missed, 
given that NPS samples were only collected during visits to the study physician; in some 
cases, parents may have considered a physician’s visit unnecessary, or parents may have 
taken their child to physicians who were not involved in the study. Respiratory viruses are 
also found in asymptomatic children (Jartti et al., 2004, Jansen et al., 2011).  Moreover in 
Study V, HBoV1 was commonly present in the nasopharynx of otitis-prone children during 
the cold period even when they were free of respiratory symptoms.  
 
In Study V, quantitative PCR detection of HBoV may offer insight into the clinical impact of 
HBoV, because HBoV at a high viral load (>10 000 copies/ml) has been associated with RTIs 
(Allander et al., 2007, Jartti et al., 2102).  However, recent publications show that HBoV PCR 
positivity of NPS alone is not a trustworthy marker for detection of acute HBoV infection 
(Söderlund-Venermo et al., 2009, Christensen et al., 2010, Martin et al., 2010, Don et al., 
2011). Serological verification of an actual infection is needed to circumvent the PCR-related 
problems of virus shedding and mucosal contamination, and to accurately diagnose an acute 
HBoV infection. Although HBoV respiratory infections can be diagnosed with moderate 
accuracy by qPCR of nasopharyngeal samples, the most reliable methods for diagnosis of 
acute symptomatic HBoV infection are PCR of serum samples and serologic analysis for IgM 
and IgG (Christensen et al., 2010). 
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2 DEVELOPMENT OF COLORIMETRIC NEUTRALIZATION TEST 
 
A novel colorimetric neutralization test (NT) was developed for the measurement of 
influenza virus antibodies. NT was applied to study the antibody response after the 
administration of a seasonal, inactivated, trivalent influenza vaccine. Antibody titers 
determined by the NT in pre- and post-vaccination serum pairs were compared with those 
obtained by the traditional hemagglutination inhibition (HI) assay. The results obtained by 
both assay methods correlated well. Moreover, the NT yielded higher pre- and post-
vaccination titers, and a larger number of significant increases in post-vaccination antibody 
titer than the HI test, indicating a higher sensitivity of this test principle. Similar 
observations have been reported in other studies (Harmon et al., 1988, Rowe et al., 1999). 
With the introduction of new vaccines against seasonal and potentially pandemic influenza, 
and with unusual subtypes of influenza A viruses occasionally causing disease in humans, 
there is an increased need for sensitive, specific and reproducible serological methods to 
study the antibody response to vaccines and to infection with wild-type viruses (Leroux-Roels 
et al., 2007, Bright et al., 2008, Ehrlich et al., 2008). Moreover, standard HI tests have 
proven to be suboptimal for measuring antibodies to H5 viruses and other influenza A viruses 
of avian origin (Rowe et al., 1999, Nicholson et al., 2001),  although the use of horse red blood 
cells appears to improve their sensitivity (Stephenson et al., 2004, Kayali et al., 2008, 
Ducatez et al., 2011).  
 
The advantage of colorimetric NT is that the colorimetric protocol does not involve any 
washing steps allowing attached and floating cells to be available for viability assessment. 
This resulted in higher reliability and reproducibility of the assay evidenced by low intra- and 
inter-assay variation. Other traditional influenza NT protocols quantify remaining infectious 
virus after the neutralization reaction and an appropriate period of incubation (Harmon et 
al., 1988, Rowe et al., 1999). Results of such assays can be skewed by several factors. Virus-
infected, weakened cells can detach from the growth surface and may be lost during the 
washing process before the cells are fixed. Trypsin added to the cell culture medium may also 
enhance such cell-loss. Reducing the number of infected cells may yield in too high titers. 
Furthermore, commonly used NTs involve several washing steps, fixation of the cells, 
incubation with specific antibodies, conjugates and substrates, i.e., processes which generate 
aerosols, produce infective and/or toxic waste, and usually last several hours (Harmon et al., 
1988, Tannock et al., 1989, Crawford-Miksza and Schnurr, 1994, Rowe et al., 1999). The 
single working step required in the colorimetric assay in order to quantify neutralizing 
antibodies after the incubation period is the addition of the tetrazolium salt-containing 
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reagent. Under biosafety level-3 laboratory working conditions, where NTs are performed 
with wild-type H5N1 and other potentially pandemic viruses, the minimization of number of 
hands-on manipulations in an assay is highly desirable. The only disadvantage of 
colorimetric NT protocol is that assay procedure involves incubation period for 48-72h, while 
other NT formats often require only 24h (Harmon et al., 1988, Rowe et al., 1999). However, 
poorly replicating viruses may not cause complete cell destruction during a short incubation 
time. Moreover, with well replicating viruses and a slightly higher virus input (e.g. 100 
pfu/assay) the incubation period can be shortened without affecting the quality of assay 
results.  
 
Considering probiotic research applications, colorimetric NT would be highly valid assay for 
studying the immune adjuvant effects of probiotics on serum influenza antibody titers.  This 
method was recently applied for studying the antibody responses elicited by chicken anemia 
virus vaccine using L. acidophilus as a live delivery vehicle (Moeini et al., 2011). In an 
influenza vaccination study in healthy adults performed with HI test, L. rhamnosus GG failed 
to improve significantly the efficacy of influenza vaccine to influenza A/H1N1 and B viruses 
(Davidson et al., 2011). One may speculate whether significant differences would have been 
observed with more sensitive and specific NT, which is able to detect lower antibody titers 
and more significant titer increases than the HI test. 
  
3 IMMUNOMODULATORY EFFECTS OF PROBIOTIC COMBINATION IN 
MACROPHAGES IN VITRO 
 
In macrophages, combination of L. rhamnosus GG (GG) and L. rhamnosus Lc705 
(Lc705) was able to induce similar or weaker proinflammatory (TNF-α, IL-6), anti-
inflammatory (IL-10), or chemokine (MCP-1, IP-10) responses as individual GG or Lc705. 
However, the cytokine responses induced by this combination were stronger than responses 
induced by Lc. lactis ARH74 (ARH74). Only few studies have characterized, whether 
combination of different strains enhances the function of the immune system synergistically 
in vitro compared with individual strains (Drouault-Holowacz et al., 2006, Castellazzi et al., 
2007, Kekkonen et al., 2008, Li et al., 2011).  Our results are in concordance with studies 
conducted in human PBMC cells, where GG and Lc705 together with PJS was inefficient in 
enhancing cytokine responses IL-10, IFN-γ, IL-12, and TNF-α over individual strains 
(Kekkonen et al., 2008). Bacteria in a combination may inhibit the immunomodulatory 
action of one another possibly by production of antagonistic agents, by competing with 
binding to the same receptor, or adhesion to the epithelium. Indeed, a recently discovered 
unique pilus structure of GG provides better adherence over Lc705 to the epithelial cells in 
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the GI tract (Kankainen et al., 2009). However, in the present study we found that 
combination of GG/Lc705 induced IL-1β 1.5 times more effectively than Lc705, suggesting 
that when including only lactobacilli genera in the combination, synergistic 
immunomodulatory effects could be achieved. Nevertheless, the use of probiotic multispecies 
of GG, Lc705, Bb99 and PJS or VSL#3 in clinical trials has shown great promise in the 
prevention of irritable bowel syndrome, Helicobacter pylori infection, or atopic eczema (Kim 
and Hodinka, 1998, Kajander et al., 2005, Kim et al., 2005, Myllyluoma et al., 2005, 
Kukkonen et al., 2007). Interestingly, all bacteria studied in the present study induced MCP-1 
and IP-10 production, and ARH74 was the strongest inducer. Thus far only GG is known to 
induce the expression of these chemokines in human macrophages (Veckman et al., 2003). In 
human DCs, ARH74 also efficiently induced IP-10 when compared with GG and Lc705 
(Latvala et al., 2008).   
 
Cytokine and chemokine profiles may provide mechanistic insight for the observed clinical 
effects of probiotics. As in other reports (Miettinen et al., 2000,Veckman et al., 2003, 
Miettinen et al., 2008), in the present study L. rhamnosus GG was able to induce low grade 
inflammation in human macrophages. Moreover, L. rhamnosus GG was effective in 
enhancing chemokine production, which is involved in promoting chemotaxis. As 
macrophages play an important role in the innate response against virus infections, probiotic 
induced low grade inflammation may enhance immune system, and recruit leukocytes to the 
infection site further facilitating viral elimination. Indeed, meta-analyses show that L. 
rhamnosus GG reduces the incidence and duration of RV diarrhea (Szajewska et al., 2007, 
Szajewska et al., 2011), and reduces the risk of RTIs in children (Hatakka et al., 2001, Hojsak 
et al., 2010b). In addition, by stimulating the production of IP-10 and MCP-1 chemokines in 
human macrophages, lactobacilli and lactococci could be efficient in promoting chemotaxis 
of leukocytes, and further enhancing the clearance of invading pathogens. In mice, L. 
rhamsosus GG has been effective in reducing RV load from the small intestine (Pant et al., 
2007). Similarly, in influenza virus infection, lactobacilli have promoted viral clearance from 
the lungs possibly by activating NK-cells (Yasui et al., 2004, Izumo et al., 2010, Nagai et al., 
2011, Takeda et al., 2011).  
 
To conclude, the ability of probiotic combination to induce immune responses in human 
macrophages differ from that of individual strains. Systematic evaluations of probiotic-
interactions in vitro are necessary prior selecting and testing the therapeutic efficacy of 
probiotic combinations in various disease conditions and in human immune status in general 
in human intervention studies. 
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4 THE EFFECTS OF NONVIABLE PROBIOTIC IN ROTAVIRUS INFECTION 
 
In RV infection nonviable GG had comparable beneficial effects as viable GG. Although, 
viable or nonviable GG did not relieve RV diarrhea, both inhibited RV infection induced 
weight reduction and RV induced colon swelling in our animal model.  Moreover, both 
animal groups receiving GG had less frequently RV in plasma, intestinal tissues, and feces 
than the RV control group. However, only viable GG was effective in reducing significantly 
the amount of RV in the colon. Only one clinical study has addressed the effects of nonviable 
/inactivated probiotics in RV diarrhea (Kaila et al., 1995). Moreover, this study did not 
include untreated control group allowing comparison between the effects of probiotic 
product forms and RV. Our results are in concordance with another study in mice (Pant et al., 
2007), where only viable GG supplementation in combination with antibodies significantly 
reduced rhesus RV load in the small intestine (Pant et al., 2007).  In the present study, viable 
GG reduced RV occurrence in plasma possibly by inducing neutralizing antibody production 
against RV. In children only live GG enhanced IgA antibody response to RV (Kaila et al., 
1995).   
 
It is likely that multiple mechanisms are involved in the probiotic-virus interaction in the 
host, and viability of a bacterium may have a role in the mechanism of action. The host-
dependent factors may have an impact on the microbiological and viral interactions as well.  
In the intestine probiotics may protect from RV by competing adhesion sites and inhibiting 
viral attachment, which in the present study was possibly seen by reduction of RV from the 
intestine by both product forms. Other studies confirm that both viable and nonviable 
lactobacilli are able to adhere to human intestinal cells (Ouwehand et al., 2000), and heat 
killed L. acidophilus LB is able to inhibit adhesion of diarrheagenic bacteria (Coconnier et al., 
1993). In macrophages and human T84 intestinal epithelial cells both viable and heat-killed 
GG are able to induce NO synthesis as well (Korhonen et al., 2001). In RV infection, infected 
enterocytes release NO (Rodríguez-Díaz et al., 2006), which may stimulate the enteric 
nervous system, and induce water secretion into a luminal space further causing diarrhea 
(Izzo et al., 1998). In the present study both GG groups suffered from diarrhea, but less RV 
was detected from their tissues. It would be interesting to speculate that by enhancing NO-
production and diarrhea, GG may inhibit RV adhesion and increase RV clearance by 
“flushing” the virus from the body. Thus, by this mechanism GG may shorten the duration, 
and enhance the recovery from RV diarrhea, as seen in several clinical studies (Kaila et al., 
1992, Isolauri et al., 1994, Majamaa et al., 1995, Guarino et al., 1997, Guandalini et al., 2000). 
Alleviation of RV infection may also be due to anti-inflammatory effect.  In the present study, 
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RV infection increased colon weight probably by enhancing inflammation and promoting 
tissue swelling by activating cytokine and chemokine responses (IFN-α, IL-8, IP-10) of 
intestinal epithelial cells (Rollo et al., 1999). Both viable and nonviable GG, however, reduced 
colon weight, which may result from the GG’s ability to decrease proinflammatory mediators 
(TNF-α, IL-1β), and increase anti-inflammatory mediators (IL-10) (Zhang et al., 2005, Li et 
al., 2009). In Study II, GG also induced anti-inflammatory IL-10 production in macrophages.  
Probiotics may also elicit anti-RV effects via stimulating adaptive immune responses. In the 
present study, viable GG was more effective than nonviable GG in reducing RV quantity in 
plasma. Moreover in children, viable GG has been more effective in stimulating RV IgA 
responses (Kaila et al., 1995). The effects of nonviable bacteria may depend further on the 
method of inactivation. For instance, inactivation by heat or irradiation may disrupt the 
surface protein conformation of the bacterium thereby inhibiting the ability of a bacterium to 
adhere to the epithelial cell (Ouwehand et al., 2000). However, if anti-RV effects are due to 
secreted bioactive or antimicrobial peptides (Yan et al., 2007, Lu et al., 2009), GG needs to be 
viable. 
 
In the future, the potential effect of probiotic induced NO production on RV infection clearly 
deserves further attention. In addition, histological examination of the rat intestines treated 
with GG would provide more information on the mechanisms underneath (Pant et al., 2007, 
Preidis et al., 2012). Furthermore, identification of the key factors defining probiotic viability 
is necessary in order to evaluate the value of nonviable probiotics in virus infections. In a 
similar manner, it may be important to assess the impact of probiotic processing methods on 
the pathogen probiotic interaction (Grześkowiak et al., 2011). Finally, it would be of 
importance to verify the effectiveness of nonviable probiotics in human intervention studies. 
As noroviruses are second to RVs as causative agents of acute gastroenteritis in children 
(Puustinen et al., 2011, Räsänen et al., 2011b), future studies could  focus on specific 
probiotics and their ability to alleviate the symptoms of these infections as well.  
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5 PROBIOTIC’S EFFECTS ON RESPIRATORY VIRUS INFECTIONS 
 
In the present study, we evaluated whether probiotic intervention is effective in reducing 
the occurrence of common respiratory viruses in the nasopharynx of children.  In children in 
Study IV, L. rhamnosus GG intervention did not have significant diminishing effect on the 
occurrence of respiratory viruses (HRV, HEV, ADV, influenza A and B virus, PIV1-2, RSV, or 
HBoV).  In contrast, in otitis-prone children (Study V), probiotic combination (L. rhamnosus 
GG, L. rhamnosus Lc705, B. breve 99, and P. freudenreichii JS) was able to decrease the 
nasopharyngeal presence of HBoV at high viral load three to six months after intervention. 
Many clinical trials in children have only investigated the effectiveness of probiotics on 
respiratory infections (Hatakka et al., 2001, Cobo Sanz et al., 2006, Hatakka et al., 2007, 
Rautava et al., 2009, Hojsak et al., 2010a, Hojsak et al., 2010b, Taipale et al., 2011). Only one, 
at least to our knowledge, has characterized the viral etiology of these infections to some 
extent as well (Hatakka, 2007). However, in that study no significant differences appeared 
between the study groups in HRV and HEV positivity. Our results imply that multispecies of 
probiotics may have some advantage over single strain in reducing viral occurrence in the 
children’s respiratory tract.  In the present study, a single administration of the L. rhamnosus 
GG may not have been sufficient to induce changes into the viral occurrence. In Study IV, the 
consumption of L. rhamnosus GG in milk was on average 108 cfu (Kumpu et al., 2012) with 
95% of recovery of GG in the fecal samples in the probiotic group. In Study V, the 
concentration of each strain of probiotics in combination was 8-9x109 cfu/capsule with 95% 
compliance. However, in this study the concentration of probiotics was not analyzed in fecal 
samples. Studies in children showed that L. rhamnosus GG in a concentration of 1-2x108 cfu 
slightly reduced children’s RTIs (Hatakka et al., 2001), whereas concentration 109 cfu of GG 
was able to significantly reduce the risk of RTIs (Hojsak et al., 2010a, Hojsak et al., 2010b). 
Moreover, GG in combination with B. lactis Bb12 in capsules with a concentration of 1x 1010 
cfu reduced the risk of early AOM and incidence of recurrent respiratory infections (Rautava 
et al., 2009). As the immune system undergoes a process of functional maturation through 
childhood, exposure to multiple probiotics may also accelerate the maturation of immune 
system.  In addition, in children prone to infections, which have impaired microbiota due to 
treatment with numerous antimicrobials, the effect may be more pronounced.  
 
Considering viral associated respiratory infections, L. rhamnosus GG was unable to reduce 
the number of respiratory symptoms observed at the time of a viral finding in children in 
Study IV. However, the children in the probiotic group had fewer days with respiratory 
symptoms per month than the children in the placebo group. In the present study 
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population, children who visited the study physician due to symptoms of respiratory 
infection were possibly experiencing illnesses more frequently or more severe infections than 
the main study population (Kumpu et al., 2012). One may speculate that probiotics could 
have more pronounced effect in children more susceptible to infections. In otitis-prone 
children (Hatakka et al., 2007), who are frequently ill, supplementation of L. rhamnosus GG 
in a combination tended to reduce recurrent upper RTI. Interestingly, in these otitis-prone 
children, probiotic combination reduced the recurrence of RTI episodes more if the children 
were negative to both HRV and HEV than if they were positive (Hatakka, 2007). As HRV and 
HEV were the only viruses investigated at that time, it may have been that those virus 
negative children were actually HBoV positive. Thus, it could be hypothesized that reduction 
of recurrent RTIs was due to probiotic combination’s ability to reduce HBoV occurrence.  
Indeed, increasing evidence suggests that HBoV is associated with upper and lower RTIs in 
children (Allander et al., 2007, Söderlund-Venermo et al., 2009, Christensen et al., 2010, 
Meriluoto et al., 2012). 
 
Oral administration of probiotics may reduce nasopharyngeal viral occurrence (Study V) and 
shorthen days with respiratory symptoms (Study IV) by augmenting local and systemic 
immune response through colonization of GI tract, or through colonization of tonsil tissue as 
well (Kumpu and Tikkanen et al., submitted 2012).  Few studies highlight these plausible 
effect mechanisms. In healthy adults, L. rhamnosus GG was effective immunoadjuvant for 
live-attenuated influenza vaccine H3N2 component by increasing seroprotection (Davidson 
et al., 2011). In mice, L. rhamnosus GG protected from H1N1 influenza virus infection by 
reducing viral titers, accumulated symptom rate, and increasing mice survival rates possibly 
by regulating respiratory immune responses such as pulmonary IL-1β, TNF, and MCP-1 
mRNA expression (Harata et al., 2010, Kawase et al., 2010).  Interestingly, intranasal 
administration of L. rhamnosus GG has been effective in activating immune responses 
against influenza infection in respiratory epithelia (Harata et al., 2010). Moreover, L. 
rhamnosus GG is able to activate innate defense mechanisms by nasal spray in humans 
(Skovbjerg et al., 2009). It would be tempting to speculate whether nasal administration of 
probiotics would have more pronounced effect also on viral occurrence.  
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In the future, more studies conducted with bacterial combinations in the prevention of 
respiratory infections in larger number of patients are warranted. In addition, these studies 
need to uncover the specific patient populations and the specific probiotic strains which 
could elicit beneficial effects. Moreover, nasal bacteriotherapy would be worth considering 
approach. Probiotic’s ability to enhance local and systemic innate immunity during virus 
infection is a plausible, yet unverified, effect mechanism behind beneficial effects, and an 
interesting area of future research. Inclusion of serological and immunological diagnostics in 
research experiments would have clear benefits in providing valuable information on the 
effects of probiotics in respiratory virus infections.   
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The present series of studies investigated the effects of probiotics on respiratory and 
gastrointestinal virus infections. The main findings are as follows:  
 
1. Colorimetric neutralization test was a sensitive and specific serological method for 
measuring influenza virus antibodies. This method was valid and suitable for 
influenza virus vaccine research, and could be also applied for studying immune 
adjuvant effects of probiotics on serum influenza antibody titers. 
 
2. In human macrophages combination of L. rhamnosus GG and L. rhamnosus Lc705 
induced similar or weaker immune responses than individual L. rhamnosus bacteria. 
However, the combination was more effective in inducing proinflammatory responses 
over traditional starter culture bacterium Lc. lactis ARH74. Probiotics and their 
combinations differ in their ability to elicit immunomodulatory effects in vitro. When 
applying new probiotic combinations into clinical studies, their interactions should be 
carefully evaluated. 
  
3. Nonviable L. rhamnosus GG was able to elicit comparable beneficial effects as viable 
product form in rotavirus infection. However, only viable L. rhamnosus GG reduced 
significantly rotavirus load in the colon, highlighting that viability is an important 
factor in virus infections. 
 
4. In children L. rhamnosus GG reduced days with respiratory tract symptoms. 
However, L. rhamnosus GG was not effective in reducing viral occurrence in the 
nasopharynx, suggesting that L. rhamnosus GG may be able to reduce viral 
respiratory symptoms through augmentation of systemic and local immunity. 
 
5. In otitis-prone children, a specific combination of probiotics including L. rhamnosus 
GG reduced the nasophraryngeal presence of human bocavirus. 
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